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Leukemia is the most common childhood cancer resulting from the uncontrolled 
accumulation of hematopoietic cells in the blood and bone marrow. Statins are 
pharmacological inhibitors of 3 -hydroxy-3 -methylglutaryl-CoA (HMG-CoA) 
reductase, the rate-determining enzyme in cholesterol biosynthesis. They are 
widely used as a hypolipidemic drug for treating hypercholesterolemia and 
cardiovascular diseases. Statins have been shown to possess anti-tumor effects on 
a variety of cancers. However, their modulatory effects and action mechanisms 
on myeloid leukemia cells remain poorly understood. 
In this study, fluvastatin, simvastatin, lovastatin but not pravastatin were first 
found to exhibit an anti-proliferative effect on the murine myelomonocytic 
leukemia WEHI-3B JCS cells, the human promyelocytic leukemia HL-60 cells 
and the murine macrophage-like tumor PU5-1.8 cells in a dose-dependent 
manner. Due to the relatively high potency of fluvastatin on the WEHI-3B JCS 
cells, they were then chosen for detailed mechanistic studies. Our results showed 
that fluvastatin exerted minimal direct cytotoxicity to the WEHI-3B JCS cells 
and no cytotoxicity for the thioglycollate-elicited murine peritoneal macrophages. 
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In addition, fluvastatin significantly reduced the in vivo tumorigenicity of 
WEHI-3B JCS cells in syngeneic BALB/c mice. 
Addition of famesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate 
(GGPP), but not squalene, was found to reverse the fluvastatin-mediated 
suppression on the growth of WEHI-3B JCS cells, indicating the correlation 
between the isoprenoid intermediates and the anti-proliferative effect of 
fluvastatin. Treatment of the WEHI-3B JCS cells with fluvastatin resulted in cell 
cycle arrest at the Gq/Gi phase and this was associated with the down-regulation 
of cyclin E, cdk2 and cdk6 protein expression. Fluvastatin also induced apoptosis 
in WEHI-3B JCS cells, as characterized by chromatin condensation and nuclear 
fragmentation. Mitochondrial membrane depolarization, activation of caspase-3, 
-8 and -9, as well as the release of apoptosis-inducing factor (AIF) from the 
mitochondria to the cytosol were found to be associated with 
fluvastatin-mediated apoptosis, suggesting that both caspase-dependent and 
caspase-independent apoptotic pathways might be involved. Interestingly, 
fluvastatin also induced the differentiation of WEHI-3B JCS cells as judged by 
morphological criteria. Moreover, nitric oxide (NO) production by 
lipopolysaccharide (LPS)-treated murine peritoneal macrophages was enhanced 
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after fluvastatin treatment. Collectively, our results showed that fluvastatin could 
exhibit in vitro and in vivo anti-proliferative effect on the murine 
myelomonocytic leukemia WEHI-3B JCS cells by inducing cell cycle arrest, 
apoptosis and differentiation of the leukemia cells. Further investigations are 
needed to explore the underlying molecular mechanisms and signaling pathways 
that might be involved in the anti-leukemic activities of fluvastatin. 
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Chapter 1 General Introduction 
1.1 Hematopoiesis and Leukemia 
1.1.1 Hematopoiesis 
The blood contains diverse cell types, such as red blood cells, white blood cells 
and platelets, which have variable life span and are responsible for a wide range 
12 
of functions. The blood cells are produced in high numbers (1 x 10 ) each day 
and are derived from the hematopoietic stem cells (HSCs), a relatively small but 
rare population of progenitors (less than 0.01% of cells in the bone marrow) with 
self-renewal and multipotent characteristics (Rizo et al., 2006; Tsiftsoglou et al., 
2009). This highly coordinated and hierarchical blood cell formation process in 
which HSCs differentiate into mature blood cells is called hematopoiesis (Kondo 
et al, 2003). 
Hematopoiesis starts to occur in successive waves during embryonic 
development. At embryonic day 7.5 (E7.5), the first wave of primitive 
hematopoiesis begins in yolk sac blood islands, generating blood cells consisting 
of mainly primitive nucleated erythrocytes from mesodermal precursors 
(Dzierzak et al, 2008). This transient wave is then progressively replaced by a 
second wave of definitive hematopoiesis, which ensures the production of adult 
erythroid, myeloid as well as lymphoid cells. As primitive hematopoiesis 
2 
Chapter 1 General Introduction 
declines, cells generated from the yolk sac and aorta-gonado-mesonephros 
(AGM) region migrate to the fetal liver at around E l l , which becomes the main 
site of blood formation during mid- to late-gestation. The hematopoietic cells 
finally colonize and reside in the bone marrow towards the end of gestation. 
Eventually, the bone marrow remains to be the predominant site of definitive 
hematopoiesis throughout postnatal life (Lecuyer et al., 2004). 
HSCs must balance between self-renewal and differentiation to provide sufficient 
primitive cells to maintain normal hematopoiesis, while producing highly 
differentiated blood cells with specialized functions. This balance consists of 
dynamic interactions between HSCs and the bone marrow microenvironment 
(Attar et al., 2004). Gene regulatory networks as well as a variety of growth and 
stromal factors will determine the cells to divide asymmetrically, undergo 
differentiation, and carry out their terminal cellular functions (Whichard et al, 
2010). There are two models of hematopoiesis: the classical model and the 
myeloid-based model (Figure 1.1). 
3 
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Figure 1.1. Models of lineage commitment during hematopoiesis. (A) In 
the classical model, HSC differentiates into CMP and CLP. (B) In the 
myeloid-based model, HSC first generates CMP and CMLR The myeloid 
potential remains in the B and T cell branches even after these lineages have 
diverged. (Modified from Wada et al., 2008) 
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In the classical model, the HSC first differentiates into a common myeloid 
progenitor (CMP) and a common lymphoid progenitor (CLP). CMP produces 
erythrocytes, megakaryocytes, monocytes, gmnulocytes and myeloid dendritic 
cells. The erythrocytic and megakaryocytic lineages generate erythrocytes and 
blood platelets respectively. The monocytic lineage generates monocytes in the 
circulation and macrophages in the tissues. The granulocytic lineage generates 
granulocytes including neutrophils, eosinophils and basophils (Leung et al., 2005; 
Baneijee et al., 2010). For CLP, it generates B cells, T cells and natural killer 
(NK) cells. In the myeloid-based model, the HSC first diverges into the CMP and 
a common myelo-lymphoid progenitor (CMLP), without the existence of CLP. 
The CMLP then produces B and T cell progenitors through a bipotential 
myeloid—B progenitor and a myeloid—T progenitor stage respectively. The major 
difference between the two models is that the progenitors giving rise to B and T 
cells do not possess any myeloid potential in the classical model, while these 
lineages retain the potential to generate myeloid cells in the myeloid-based 
model (Kawamoto et al., 2010). 
The production of hematopoietic cells is under a tight control of a group of 
cytokines, collectively known as hematopoietic cytokines. These cytokines bind 
5 
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to their specific high-affinity receptors and regulate the survival, proliferation 
and differentiation of immature and maturing hematopoietic cells, as well as the 
functional activation of mature cells in the immune system (Perugini et “/., 2009). 
Some cytokines support the development of specific lineages, while others can 
regulate cells in multiple lineages. The simultaneous action of multiple cytokines 
is required for the proliferation of certain cell types, such as stem cells or 
megakaryocyte progenitors. Lineage-specific cytokines include erythropoietin 
(EPO), granulocyte colony-stimulating factor (G-CSF) and macrophage 
colony-stimulating factor (M-CSF). EPO is important for the maintenance of 
erythrocyte production. G-CSF controls the growth and differentiation of 
neutrophils, while M-CSF regulates the proliferation, differentiation and 
activation of the monocyte-macrophage lineage. Stem cell factor (SCF), 
interleukin-2 (IL-2), IL-3 and IL-7 are broad-acting cytokines, stimulating the 
growth of most lineages. It appears that immature myeloid progenitors are 
mainly sensitive to multiple cytokines while the relatively mature ones respond 
to stimulation by single cytokines, demonstrating the complex and strictly 
regulated system with considerable overlapping functions within the cytokine 
network (Leung et al., 2005; Robb, 2007; Metcalf, 2008). 
6 
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To conclude, hematopoiesis is a delicate and highly controlled process. 
Disturbance in the signaling pathways that regulate the various hematopoietic 
processes will result in aberrant hematopoiesis and is associated with the 
development of cancer, including leukemia (Reya et al., 2001). 
7 
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1.1.2 Leukemia 
1.1.2.1 Overview of leukemia 
Leukemia is a malignant disease of the blood and bone marrow. It is 
characterized by the uncontrolled accumulation of blood cells, which can be 
immature or differentiated (The Leukemia & Lymphoma Society, 2010). It is 
caused by intrinsic factors such as chromosomal abnormalities or epigenetic 
deregulation at the level of HSC and/or early multipotent hematopoietic 
progenitors, or extrinsic factors such as immune dysfunction and 
tumor-promoting microenvironment in the hematopoietic system (Lotem et al., 
2006; Ayala et al, 2009; Hu et al., 2009). Leukemic stem cells (LSCs), the 
aberrant counterpart of HSCs, are thought to play an essential role in the 
initiation, and possibly the maintenance, of leukemia (Jordan et al., 2006). They 
give rise to leukemia cells, which are transformed hematopoietic cells with 
increased resistance to cell death and disruption of differentiation (Tenen, 2003; 
Cheng, 2004; Renneville et al., 2008). These leukemia cells repopulate within 
the bone marrow and finally enter the bloodstream, resulting in the leukemic 
phenotype (Lane et al” 2009). 
8 
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1.1.2.2 Symptoms and diagnosis of leukemia 
The common symptoms of leukemia include weight loss (for unknown reason), 
paleness or easy fatigue (due to anemia), fever or night sweats, swollen lymph 
nodes, pain in the bones and joints, abdominal swelling or discomfort (because 
of swollen spleen or liver), repeated minor infections or poor healing (due to 
inadequate white cell count), easy bruising or bleeding (as a result of platelet 
deficiency), nose-bleeds or other hemorrhages. These general symptoms are 
similar to those of other less serious conditions, resulting in difficulties for early 
diagnosis of leukemia. Hence, diagnosis of leukemia requires specific blood tests 
or bone marrow biopsy to examine the cells in the blood and bone marrow 
(American Cancer Society, 2009; National Cancer Institute, 2010a; The 
Leukemia & Lymphoma Society, 2010). 
1.1.2.3 Classification of leukemia 
Leukemia can be classified based on the rate of progression of the disease. Acute 
leukemia is a rapidly progressing disease which leads to the accumulation of 
immature and non-functional cells in the blood and bone marrow. Chronic 
leukemia progresses slowly and the leukemia cells are relatively mature than 
those in acute leukemia. Leukemia can also be grouped into myeloid or 
9 
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lymphocytic according to the developmental lineage of the affected cells. 
Consequently, there are four common types of leukemia when the two criteria are 
considered together, namely acute myeloid leukemia (AML), acute lymphocytic 
leukemia (ALL), chronic myeloid leukemia (CML) and chronic lymphocytic 
leukemia (CLL) (The Leukemia & Lymphoma Society, 2010). 
In addition, the four categories of leukemia can be further divided into several 
subtypes using different classification systems. According to the 
French-American-British (FAB) system, AML can be classified into subtypes MO 
to M7 based on the maturity and type of affected cells, and ALL can be divided 
into subtypes LI to L3 based on the morphology of leukemia cells (Table 1.1). 
CML is classified into 3 phases based on the number of myeloblasts present in 
the blood or bone marrow and CLL is divided into 5 stages according to the Rai 
system (Table 1.2) (American Cancer Society, 2010; National Cancer Institute, 
2010b). 
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Table 1.1. Classification of acute leukemia. 
Type Subtype Description 
MO undifferentiated acute myeloblastic leukemia 
acute myeloblastic leukemia with minimal 
Ml . 
maturation 
M2 acute myeloblastic leukemia with maturation 
A^ciite • 
M3 acute promyelocytic leukemia 
myeloid acute myelomonocytic leukemia 
leukemia ^ . 1 1 . •丄飞 
acute myelomonocytic leukemia with 
(AML) M4 eos 
eosinophilia 
M5 acute monocytic leukemia 
M6 acute erythroid leukemia 
M7 acute megakaryoblastic leukemia 
Acute LI T cell or pre-B cell (more mature) 
lymphocytic L2 T cell or pre-B cell (immature and pleomorphic) 
leukemia ” 
L3 B cell 
(ALL) 
(American Cancer Society, 2010; National Cancer Institute, 2010b) 
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Table 1.2. Classification of chronic leukemia. 
Type Subtype Description 
Chronic Chronic phase < 10% blasts in blood or bone marrow 
myeloid Accelerated … " . " , , 
, 10% -19% blasts in blood or bone marrow 
leukemia phase 
(CML) Blast phase ^ 20% blasts in blood and/or bone marrow 
absolute lymphocytosis (> 15,000 
lymphocytes/mm of blood) without 
Stage 0 二 ！ 1 1 / 
adenopathy, hepatosplenomegaly, anemia or 
thrombocytopenia 
absolute lymphocytosis with 
lymphadenopathy without 
Stage I / … 丨 . 
nepato splenomegaly, anemia or 
thrombocytopenia 
absolute lymphocytosis with either 
lymphocytic stage II hepatomegaly or splenomegaly with or 
leukemia . , , , , , 
without lymphadenopathy 
(CLL) -
absolute lymphocytosis and anemia 
(hemoglobin < 1 1 g/dL) with or without 
Stage III lymphadenopathy, hepatomegaly or 
splenomegaly 
absolute lymphocytosis and 
thrombocytopenia (< 100,000/mm^) with or 
Stage IV without lymphadenopathy, hepatomegaly, 
splenomegaly or anemia 
(American Cancer Society, 2010; National Cancer Institute, 2010b) 
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1.1.2.4 Epidemiology of leukemia 
Leukemia is the most common type of childhood cancer. In Hong Kong, 
leukemia constitutes 28.7% of the total cancer in children and adolescents 
(Figure 1.2) (Hong Kong Cancer Registry, 2009). In the United States, leukemia 
is one of the top 15 most frequently occurring types of cancer and the most 
common (27%) cancer occurring among children less than 20 years. The key 
statistics for the four different types of leukemia are summarized in Table 1.3 
(The Leukemia & Lymphoma Society, 2010). Briefly, AML has a high incidence 
rate, the lowest five-year relative survival rate and expected to cause the highest 
number of deaths among the four types of leukemia. 
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Most Common Cancers in Children and Adolescents 
(0-19 years) in Hong Kong (2003 一 2007) 
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fMi -0 \ … 
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， 、 , i M l P " ^ • others 
Figure 1.2. The most common cancers in children and adolescents (0-19 
years) in Hong Kong (2003 - 2007). (Modified from Hong Kong Cancer 
Registry, 2009) 
Table 1.3. Key statistics for the four types of leukemia in the United 
States. 
Incidence rate Five-year 
(per 100,000 relative survival Estimated deaths 
Type of leukemia 卩 叩 r a t e in 2009 
(2002-2006) (1999-2005) 
Acute myeloid 3 5 23.4% 9,000 
leukemia (AML) 
Chronic myeloid ^ 3 53.3% 470 
leukemia (CML) 
Acute 
lymphocytic 1.6 66.3% 1,400 
leukemia (ALL) 
Chronic 
lymphocytic 4.1 78.8% 4,390 
leukemia (CLL) 
(The Leukemia & Lymphoma Society, 2010) 
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1.1.2.5 Conventional treatments for leukemia 
The ultimate goal for leukemia treatment is to achieve a complete remission, 
meaning that there is no evidence for disease and the individual becomes healthy 
again with normal blood and marrow cells. Complete remission for five years 
after diagnosis is regarded as an indication for long term survival (The Leukemia 
& Lymphoma Society, 2010). The conventional treatments for leukemia include 
chemotherapy, radiotherapy and hematopoietic stem cell transplantation. 
(1) Chemotherapy 
Chemotherapy, which is the application of drugs to destroy leukemia cells, is the 
most effective strategy for treating leukemia. The chemotherapeutic drugs 
include alkylating agents, anti-metabolites, anti-tumor antibiotics, folate 
analogues, mitotic blockers and cell cycle inhibitors, which directly kill the 
tumor cells or arrest them at a specific phase of the cell cycle to stop their growth 
(Tsiftsoglou et al., 2003). The general chemotherapeutic treatment includes one 
course of intensive induction therapy, an additional course of intensive 
consolidation therapy and maintenance therapy. In induction therapy, 
chemotherapeutic drugs are usually administered through a catheter placed into a 
vein in the upper chest of the patient. Anthracyclines and cytarabine (AraC) are 
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currently the major drug combinations employed. Consolidation therapy consists 
of additional courses of intensive chemotherapeutic treatment usually with higher 
doses of the same drugs used during induction therapy, intending to give a cure 
and prevent relapse in patients after induction therapy. High-dose AraC 
(HDAraC) is currently the standard drug for patients aged less than 60 years. 
Maintenance therapy aims to further reduce the number of residual leukemia 
cells and prevent the occurrence of relapse in patients who have previously 
reached complete remission. It is thought to possess less myelosuppressive effect 
than induction and consolidation therapies (Robak et al., 2009). 
(2) Radiotherapy 
Radiotherapy involves the use of X-rays or high energy rays to kill leukemia 
cells (Featherstone et al., 2005). It is usually used together with chemotherapy. 
Radiation can be applied to a specific body area where leukemia cells are 
situated or to the whole body before bone marrow transplantation. External beam 
radiation is often used for radiotherapy. Current delivery methods for 
radiotherapy are improved and less radiation is spread to neighboring healthy 
tissues (The Leukemia & Lymphoma Society, 2010). 
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(3) Hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation (HSCT) is crucial for treating blood 
cancers in both children and adults. The hematopoietic system of the patient is 
first eliminated and replaced with healthy hematopoietic stem cells afterwards in 
order to restore the normal function of the bone marrow. There are two types of 
HSCT: autologous transplantation, in which the own cells of the patients are 
harvested and infused back, and allogeneic transplantation, in which the matched 
cells from a donor are collected and transplanted into the patient (Dreger, 2009). 
For both types of transplantation, the stem cells are usually harvested from the 
blood circulation, though they may be collected from the bone marrow or even 
from the umbilical cord blood in some cases. In fact, a higher risk of relapse is 
linked to an autologous transplant. However, an allogeneic transplant gives a 
higher risk for serious side effects of the transplantation procedure, or death. 
Hence, the use of autologous or allogeneic transplantation depends on the 
leukemia type, individual age, other possible effective therapies and the 
availability of astern cell donor (The Leukemia & Lymphoma Society, 2010). 
Although these treatments are routinely used nowadays, they do have their side 
effects and limitations. The effect of chemotherapy and radiotherapy is 
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non-specific, they kills not only the leukemia cells but also the rapidly 
proliferating normal cells. The rapid breakdown of leukemia cells during 
chemotherapy may result in tumor lysis syndrome that often leads to a high rate 
of morbidity and mortality. Radiotherapy may affect the normal function of the 
treated organs. HSCT requires a high cost and is difficult to find human 
leukocyte antigen (HLA)-compatible donors. Therefore, researchers are trying to 
improve the current strategies or develop new and effective methods for 
leukemia treatment (Leung et al., 2005). 
1.1.2.6 Novel approaches to leukemia treatment 
Dose elevation of currently available cytotoxic drugs is unlikely to improve 
clinical outcomes in post-remission therapy in leukemia (Robak et al., 2009). 
Development of new treatment and targeted therapies for leukemia is thus 
essential. Some of the new drugs with anti-leukemia potentials include 
BCR-ABL tyrosine kinase inhibitors such as imatinib mesylate (Gleevec®), 
hypomethylating agents such as azacitidine (Vidaza®), monoclonal antibodies 
such as Lintuzumab, immunotoxins such as Gemtuzumab ozogamicin 
(Mylotarg®) and proteasome inhibitors such as bortezomib (Velcade®). They 
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have entered clinical trials and most of them are used in combination with other 
classical drugs (Robak et al., 2009; The Leukemia & Lymphoma Society, 2010). 
It has been demonstrated that leukemia cells possess chromosomal alterations 
that generate aberrant oncogenic fusion proteins, disturbing the normal cell 
signaling processes and result in uncontrolled proliferation, increased tolerance 
to apoptosis and blocked cell differentiation. These processes, especially the 
apoptosis and differentiation machinery, are thus targeted by new strategies for 
treating leukemia. The camptothecin analog NSC606985 was shown to induce 
apoptosis of AML cells by activation of protein kinase C 5 (PKC S), loss of 
mitochondrial membrane potential and activation of caspase-3, affecting the 
expression of proteins responsible for DNA repair, chromosome assembly, 
mRNA processing, biosynthesis, modification and degradation of proteins (Chen 
et al, 2007). 
All-trans retinoic acid (ATRA) is a successful example of 
differentiation-inducing drugs for acute promyelocytic leukemia (APL). The 
chromosome translocation t(15,17) in APL is responsible for the flision of the 
promyelocytic leukemia (PML) gene on chromosome 15 and the retinoic acid 
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receptor a (RARa) on chromosome 17, resulting in the PML-RARa fusion 
protein. This fusion protein suppresses gene transcription and blocks cell 
differentiation. ATRA was shown to be capable of cleaving the flision protein and 
promotes the differentiation of leukemia cells, leading to complete remission of 
the disease, though retinoic acid resistance and relapse are commonly seen (Chen 
et al., 2007; Hamilton et al., 2010). 
Besides apoptosis and differentiation pathways, cholesterol modulation is 
another potential therapeutic area for leukemia. Rapidly dividing tumor cells 
require a high rate of membrane lipid biosynthesis. Thus, the cellular cholesterol 
content is important for maintaining membrane structure and function. 
Cholesterol metabolism is dysregulated in many malignancies, including myeloid 
leukemia (Li et al., 2006). In addition, cholesterol level as well as mRNA 
expression of 3 -hydroxy-3 -methylglutaryl-CoA (HMG-CoA) reductase and low 
density lipoprotein (LDL) receptor were increased in primary AML samples after 
in vitro exposure to chemotherapy. Blocking these acute cholesterol responses 
was able to sensitize the AML cells to chemotherapy (Banker et al., 2004). These 
cholesterol responses may be responsible for therapeutic failure in AML patients. 
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As a result, cholesterol-modulating agents may have a potential therapeutic role 
in the treatment of leukemia. 
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1.2 Statins 
1.2.1 Overview of statins 
Statins are efficient inhibitors of 3 -hydroxy-3 -methylglutaryl-CoA (HMG-CoA) 
reductase, the rate-determining enzyme in cholesterol biosynthesis (Figure 1.3). 
They are widely used for the treatment of hypercholesterolemia and 
cardiovascular diseases, which are correlated with increased plasma cholesterol 
levels (Campbell et al., 2006). Nine statins have been tested for clinical use. 
Mevastatin is the prototype and natural statin isolated from Penicillium citrinum. 
Lovastatin is also a natural statin and derived from Aspergillus terreus. 
Pravastatin and simvastatin are modified derivatives of lovastatin, while 
atorvastatin, cerivastatin, fluvastatin, pitavastatin and rosuvastatin are all fully 
synthetic. Statins are generally accepted as safe and well-tolerated drugs. Serious 
side effects resulted from statin treatment are rare, except for the withdrawal of 
cerivastatin from the market in 2001 due to fatal rhabdomyolysis (Furberg et al., 
2001). Statins are usually administered orally at 10 - 80 mg/day for 
cholesterol-lowering (Dulak et al., 2005). 
2 2 
Chapter 1 General Introduction 
Acety l -CoA 
A cet 0 acetyl-C oA 
i 1 
H M G - C o A 
i 
I 














Dolichois Fai i ies j i -PP — ^ Geranjdgeraiiyi-PP 
\ i 
Prei iykted proteins 





Figure 1.3. The cholesterol biosynthesis pathway. 
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1.2.2 Chemical structures of statins 
The chemical structures of various statins are shown in Figure 1.4. Statins have a 
structure that mimic HMG-CoA, the natural substrate of HMG-CoA reductase. 
Studies on the protein structures of the catalytic portion of the enzyme that 
complexed with six different statins suggested that statins competitively inhibit 
HMG-CoA reductase by binding to the active site of the enzyme, thereby 
sterically hindering the access of the natural substrate. There is also a 
rearrangement of the substrate-binding pocket of the enzyme, favoring the 
accommodation of the structurally diverse, rigid and hydrophobic groups of 
statins (Istvan et al., 2001). Moreover, statins have different hydrophobicity. 
Atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin and simvastatin are 
relatively lipophilic, while pravastatin and rosuvastatin are relatively hydrophilic 
in nature (Neubauer et al., 2003; Schachter, 2005). The difference in their 
solubility profile may thus result in different pharmacokinetic properties and 
actions. 
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Figure 1.4. The chemical structures of different statins. 2 5 
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1.2.3 Pharmacokinetics of statins 
The major pharmacokinetic properties of different statins are summarized in 
Table 1.4. All statins are administered as their active hydroxy! acid form, except 
for lovastatin and simvastatin, which are taken as their lactone form and 
enzymatically hydrolyzed to their active form in the body. The Km values of 
statins lie in the nanomolar range. Thus, statins have a high affinity to HMG-CoA 
reductase and effectively displace HMG-CoA which binds to the enzyme at 
micromolar concentrations. The solubility of statins depends on the chemical 
structure of individual statins. This in turn affects their absorption, distribution, 
metabolism and excretion. In general, statins have short elimination half-lives of 
less than 3 hours, but those of pitavastatin, atorvastatin and rosuvastatin can 
reach 11, 14 and 19 hours respectively (Schmitz et al., 2002; Schachter, 2005). 
Statins are bound by serum proteins (except pravastatin) and their systemic 
bioavailability is limited, probably due to extensive first-pass uptake at the 
hepatic level (Garcia et al., 2003). All statins are relatively hepatoselective for 
the inhibition on HMG-CoA reductase, as the majority of endogenous cholesterol 
is produced in the liver. Lipophilic statins enter hepatocytes and non-hepatic cells 
primarily by passive diffusion. This is responsible for the efficient first-uptake. 
On the other hand, carrier-mediated uptake is the major machinery for 
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hydrophilic statins and thus they primarily target on hepatocytes. Lipophilic 
statins (except pitavastatin) but not the hydrophilic ones are predominantly 
metabolized by the cytochrome P450 (CYP450) system in the liver (Bellosta et al, 
2004). The hydrophobic nature of lipophilic statins allows them to penetrate cell 
membranes effectively and result in pleiotropic effects in extrahepatic cells, in 
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1.2.4 Pleiotropic effects of statins 
Despite the cholesterol-lowering properties, statins have recently been shown to 
possess pleiotropic effects, including anti-inflammation, immunomodulation, 
anti-angiogenesis as well as anti-tumor activities. 
1.2.4.1 Anti-inflammatory and immunomodulatory effects of statins 
Local inflammation plays a central role in atherogenesis and other chronic 
progressive diseases. Statins have been shown to have anti-inflammatory 
properties mediated by the suppression of the synthesis of inflammatory 
cytokines and the expression of adhesion molecules such as intercellular 
adhesion molecule-1 (ICAM-1) involved in the recruitment of inflammatory cells. 
They are able to reduce the expression of major histocompatibility complex class 
II (MHC-II) in endothelial cells and macrophages and thus inhibit T cell 
activation (Ferrara et al., 2003). In addition, statins can enhance endothelial nitric 
oxide (NO) production through up-regulation of endothelial NO synthase (eNOS) 
(Chopra et al., 2007). In an animal model of chronic renal disease, inhibition of 
cytokine expression by statins reduced histologic evidence of glomerular injury, 
mesangial cell proliferation, tubulointerstitial inflammation and fibrosis 
(Forrester et al., 2007). The anti-inflammatory and immunomodulatory effects of 
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statins may thus reduce the incidence of rejection and enhance the long term 
survival of patients in pulmonary, cardiac or renal transplantation (Samson et al., 
2005). 
1.2.4.2 Anti-angiogenic effects of statins 
Angiogenesis is the formation of new blood vessels from pre-existing vascular 
network. It is of great importance during embryonic development and becomes 
adaptive for the regeneration of damaged body parts after birth. Nevertheless, it 
also plays an important role in pathological conditions such as tumor, in which 
angiogenesis provides oxygen and nutrients for the growing tumor cells (Dulak, 
2005). Low doses of statins at nanomolar concentrations can induce 
pro-angiogenic effects by stimulating Akt-dependent vascular endothelial cell 
survival. It is considered as beneficial for the treatment of cardiovascular 
diseases. However, high doses of statins at micromolar concentrations exhibit 
anti-angiogenic activities, which may be important for cancer therapies (Dulak et 
al., 2005). However, there are reports showing that statins can be angiogenic at 
high doses. Therefore, the effects of statins on angiogenesis are still controversial 
(Liao et a/., 2005). 
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1.2.4.3 Anti-tumor effects of statins 
In recent years, there are increasing studies on the use of statins as anti-cancer 
drugs on a variety of malignant cells and tissues, including breast cancer 
(Ghosh-Choudhury et al, 2010), colon cancer (Yasuda et al., 2010), lung cancer 
(Hwang et al, 2010) and prostate cancer (Kollmeier et al., 2010). Statins are able 
to inhibit the proliferation of tumor cells through different mechanisms. 
Inhibition of cholesterol biosynthesis pathway by statins can reduce the 
production of isoprenoid intermediates, thereby inhibiting the post-translational 
modification of proteins important for cell growth and proliferation and this in 
turn resulting in tumor growth suppression (Gbelcova et al, 2008). Statins may 
trigger apoptosis of tumor cells via the down-regulation of the NF-KB pathway 
(Campbell et al., 2006), stimulation of the JNK pathway (Ahn et al., 2008) or the 
activation of caspases (Tomiyama et al., 2008). Induction of tumor cell 
differentiation is also possible after statin treatment (Sassano et al., 2007). In 
addition, statins can also be administered together with the classical 
chemotherapeutic drugs for treating malignancies to achieve greater beneficial 
outcomes. Fluvastatin and daunorubicin had been shown to display synergistic 
cytotoxic effect in AML cells (Calabro et al., 2008), while fluvastatin was 
reported to attenuate the doxorubicin-induced cardiotoxicity in mice (Riad et al., 
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2009). Therefore, the underlying mechanisms for the anti-tumor activities of 
statins vary among different cancer cell types. 
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1.3 Objectives and scope of the present study 
Statins are potent inhibitors of HMG-CoA reductase in cholesterol biosynthesis 
pathway and have been demonstrated to possess pleiotropic effects. However, 
their modulatory effects on myeloid leukemia remain poorly understood. In this 
study, the anti-tumor effects of statins on myeloid leukemia cells would be 
investigated both in vivo and in vitro. Attempts had been made to elucidate the 
underlying cellular and molecular mechanisms for the anti-tumor activities of 
statins so as to explore strategies which could enhance the anti-tumor properties 
of statins. 
In Chapter 3 of this thesis, the effects of various statins, including fluvastatin, 
simvastatin, lovastatin and pravastatin, on the proliferation of the murine 
myelomonocytic leukemia WEHI-3B JCS cells, the human promydocytic 
leukemia HL-60 cells and the murine macrophage-like tumor PU5-1.8 cells were 
first examined. In view of the relatively high potency of fluvastatin，subsequent 
studies were then focused on the modulatory effects and action mechanisms of 
fluvastatin on the murine myeloid leukemia WEHI-3B JCS cells. The 
cytotoxicity, kinetics and reversibility of the anti-proliferative effect of 
fluvastatin, and its association with the cholesterol biosynthesis pathway were 
3 3 
Chapter 1 General Introduction 
Studied. The effects of fluvastatin on the in vivo tumorigenicity, the cell cycle 
profile and protein expression of cell cycle regulatory proteins were also 
examined. In Chapter 4, the effects of fluvastatin on the apoptosis of WEHI-3B 
JCS cells were investigated in terms of chromatin condensation, DNA 
fragmentation, mitochondrial membrane potential, caspase activities and 
expression of the pro-apoptotic protein AIF, while the differentiation-inducing 
effect of fluvastatin on WEHI-3B JCS cells was examined by morphological 
staining and flow cytometric analysis. It is envisaged that this project can provide 
better insights into novel strategies for leukemia treatment with high efficacy and 
minimal side effects. 
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Animals 
Inbred female BALB/c (haplotype H-2'^ ) mice, aged 6 to 8 weeks old, were 
bred under specific pathogen-free condition at the University Laboratory 
Animal Services Centre of The Chinese University of Hong Kong. They 
were given free access to rodent diet (Chow 5001, Rodent Laboratory) and 
tap water. Experiments were conducted with the licence under Section 7 of 
the Animals (Control of Experiments) Ordinance, Chapter 340 issued by the 
Department of Health, The Government of Hong Kong Special 
Administrative Region, following the guidelines of the Animal 
Experimentation Ethics Committee of The Chinese University of Hong 
Kong. 
2.1.2 Cell lines 
(1) WEHI-3B 
The murine myelomonocytic leukemia WEHI-3B D" cell line is a mineral 
oil-induced tumor from BALB/c mice. It was originally received from Dr. D. 
Metcalf (Walter and Eliza Hall Institute for Medical Research, Melbourne, 
Australia) and subsequently subcloned by the Experimental Hematology 
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Group, John Curtin School of Medical Research, Australian National 
University, Canberra, Australia. The subclone designated as WEHI-3B JCS 
(Mak et al” 1993) was used in this study. 
(2) HL-60 
HL-60 (ATCC Number CCL-240) is a human promyelocytic leukemia cell 
line derived from the peripheral blood leukocytes of a 36-year-old 
Caucasian female with acute promyelocytic leukemia (Collins et al, 1977). 
It was purchased from the American Type Culture Collection (ATCC). 
(3) PU5-1.8 
PU5-1.8 is a macrophage-like tumor derived from BALB/c mice (Ralph et 
al, 1976). It was obtained from the Department of Pathology, University of 
Cambridge, U.K. 
2.1.3 Cell culture media, buffers and other reagents 
2.1.3.1 Cell culture media and reagents 
(1) Roswell Park Memorial Institute fRPMI) 1640 medium 
RPMI 1640 powder (Gibco, Cat. No. 23400-021), containing 2 mM 
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L-glutamine and 25 mM 4-(2-hydroxyethyl)-1 -piperazineethanesulfonic 
acid (HEPES), was stored at 4°C until use. The powder was dissolved in 
deionized water and buffered with 2 g sodium bicarbonate (NaHCOa) 
(Sigma, Cat. No. S6014) per litre. The solution was adjusted to pH 7.2 by 1 
M hydrochloric acid (HCl) or sodium hydroxide (NaOH). The medium was 
then sterilized by membrane filtration through a 0.22 |im filter unit 
(Millipore, Cat No. SCGPT05RE) and stored at 4°C before use. 
Plain RPMI medium was prepared by adding 1% antibiotics to RPMI 
medium. Complete RPMI medium, prepared by supplementing plain RPMI 
medium with 10 or 20% fetal bovine serum (FBS), was used for continuous 
subculturing of cells. WEHI-3B JCS and PU5-1.8 cells were cultured with 
complete RPMI medium supplemented with 10% FBS while HL-60 cells 
were cultured with 20% FBS-supplemented medium. Heat-inactivated FBS 
(HI-FBS) was used to supplement plain RPMI medium instead if the cells 
were to be used for bioassays. 
(2) Serum supplements 
Fetal bovine serum (FBS) (Gibco, Cat No. 16000-044) was stored as 50 mL 
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aliquots at -20°C. Heat-inactivated fetal bovine serum (HI-FBS) was 
prepared by heating FBS at 56 for 30 minutes and stored at -20°C before 
use. 
(3) Antibiotics 
Antibiotic-antimycotic or penicillin-streptomycin-fungizone (PSF) solution 
(Gibco, Cat. No. 15240-062) contains 10,000 units/mL penicillin G (sodium 
salt), 10,000 |ig/mL streptomycin sulfate and 25 jiig/mL amphotericin B as 
fungizone or antimycotic in 0.85% saline. The lOOX antibiotics mixture was 
stored as 5 mL aliquots at -20�C before use. It was used in the preparation of 
plain RPMI and complete RPMI media at a final concentration of 1%. 
(4) Dulbecco's phosphate buffered saline (PBS) 
PBS powder (Gibco, Cat. No. 21600-069), without calcium chloride and 
magnesium chloride, was stored at 4°C. For preparing PBS, the powder was 
dissolved in deionized water and the solution was adjusted to pH 7.4 by 1 M 
HCl or NaOH. It was then sterilized by autoclaving at 12rC for 20 minutes 
and stored at room temperature before use. 
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2.1.3.2 Drugs and chemicals 
(1) Statins 
(a) Fluvastatin 
Fluvastatin sodium salt (Alexis, Cat No. ALX-270-466) with > 98% 
purity was dissolved in deionized water to give a stock solution of 50 
mM. The stock solution was stored at -20°C in dark until use. 
(b) Simvastatin 
Simvastatin powder (Alexis, Cat. No. ALX-430-104) with > 98% purity 
was dissolved in dimethyl sulphoxide (DMSO) (Sigma, Cat. No. D2650) 
to give a stock solution of 50 mM. The stock solution was stored at 
-20OC in dark until use. 
(c) Lovastatin 
Lovastatin powder (Alexis, Cat. No. ALX-430-103) with > 98% purity 
was dissolved in DMSO to give a stock solution of 50 mM. The stock 
solution was stored at -20°C in dark until use. 
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(d) Pravastatin 
Pravastatin sodium salt (Sigma, Cat.No. P4498) with > 98% purity was 
dissolved in deionized water to give a stock solution of 50 mM. The 
stock solution was stored at -20°C in dark until use. 
(2) Intermediates of cholesterol biosynthesis pathway 
(a) Famesyl pyrophosphate (FPP) 
FPP solution (Sigma, Cat. No. F6892) with > 95% purity has a 
concentration of 2.31 mM. This stock solution was stored at -20°C in 
dark until use. 
(b) Geranylgeranyl pyrophosphate (GGPP) 
GGPP solution (Sigma, Cat. No. G6025) with > 95% purity has a 
concentration of 2.22 mM. This stock solution was stored at -20�C in 
dark until use. 
(c) Squalene (SO) 
Squalene solution (Sigma, Cat. No. S3626) with > 98% purity has a 
concentration of 2.09 M. This stock solution was stored at 4°C in dark 
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until use. 
(3) Lipopolysaccharide (LPS) 
The powdered form of LPS from Escherichia coli 026:B6 (Sigma, Cat. No. 
L2654) was dissolved in PBS to give a stock solution of 1 mg/mL. The 
stock solution was stored at -20°C in dark until use. 
2.1.3.3 Reagents and buffers for primary culture 
(1) Thiogivcollate (TG) broth 
The 3% (w/v) TG broth was prepared by suspending 3 g dehydrated TG 
powder (Difco, Cat. No. 0236-01-5) in 100 mL deionized water. The 
solution was heated until the powder was completely dissolved. It was then 
sterilized by autoclaving at 121�C for 20 minutes and stored at room 
temperature in dark for at least one month before use. 
(2) Red blood cell Ivsis buffer (ACK buffer) 
The buffer was prepared by suspending 8.3 g NH4CI (Sigma, Cat. No. 
A9394), 1 g KHCO3 (Sigma, Cat. No. P9144) and 1.8 mL 5% 
ethylenediaminetetraacetic acid (EDTA) (USB, Cat. No. 15701) in one litre 
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deionized water to give a final concentration of 150 mM NH4CI, 1 mM 
KHCO3 and 0.001 mM EDTA. The buffer was adjusted to pH 7.2 by 1 M 
HCl or NaOH. It was then sterilized by membrane filtration through a 0.22 
jim filter unit and stored at 4°C before use. 
2.1.3.4 Dye solutions 
(1) Trypan blue 
Trypan blue solution (Gibco, Cat. No. 15250-061) containing 0.4% (w/v) 
trypan blue in 0.85% saline was stored at room temperature before use. 
(2) Hemacolor® staining solution set 
The staining solution set consists of three different solutions for 
morphological staining of cells on microscopic glass slides. Hemacolor® 
solution 1 (Merck, Cat. No. 111955) is a fixation solution, Hemacolor® 
solution 2 (Merck, Cat. No. 111956) is a red colour reagent and Hemacolor® 
solution 3 (Merck, Cat. No. 111957) is a blue colour reagent. They were 
kept in tightly closed glass bottles and stored in dark at room temperature. 
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2.1.3.5 Reagents for cell proliferation assays 
(1) 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenvl tetrazolium bromide (MTT) 
MTT powder (USB, Cat. No. US 19265) was dissolved in PBS to give a 
stock solution of 4 mg/mL. The stock solution was stored at 4°C in dark 
until use. 
(2) [Methvl^HI Thymidine (^H-TdR) 
The ^H-TdR stock solution (Amersham, Cat. No. TRA310-5MCI) 
possessing a specific activity of 2.0 Ci/mmol was stored as 500 |LIL aliquots 
at before use. 
(3) Liquid scintillation cocktail 
OptiPhase HighSafe 2 liquid scintillation cocktail (PerkinElmer, Cat. No. 
1200-436) based on the solvent di-isopropylnaphthalene (DIN) was stored 
in dark at room temperature. 
2.1.3.6 Reagents and buffers for flow cytometry 
(1) Propidium iodide (PI) DNA staining buffer 
The PI DNA staining buffer, containing 20 [ig/mL PI (Sigma, Cat. No. 
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P4170) and 8 jig/mL ribonuclease A (RNase A) (Amersham, Cat. No. 
E78020Y) in PBS, was freshly prepared and kept at in dark before use. 
(2) 5,5，,6,6，-tetrachloro-1, r ,3,3 ’-tetraethylbenzimidazolylcarbQcyanine iodide 
(JC-1) staining solution 
JC-1 powder (Molecular Probes, Cat. No. T-3168) was dissolved in DMSO 
to give a 5 mg/mL stock solution. The stock solution was stored at -20°C in 
dark until use. 
2.1.3.7 Reagents for Hoechst staining 
(1) Paraformaldehyde 
Two grams of paraformaldehyde powder (Sigma, Cat. No. P6148) was first 
added to 50 mL deionized water and dissolved by heating at 60�C for 1 hour. 
A few drops of NaOH were added to facilitate the dissolution until the 
solution became clear. After cooling, 50 mL 2X PBS was added to form 4% 
(w/v) paraformaldehyde in IX PBS. The solution was stored at 4°C in dark 
until use. 
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(2) Hoechst 33342 
Hoechst 33342 (Molecular Probes, Cat. No. H-3570), with a concentration 
of 10 mg/mL，is a cell permeable nucleic acid stain with blue fluorescence. 
It was stored at 4°C in dark until use. 
2.1.3.8 Reagents and buffers for DNA isolation 
(1) IGEPAL CA-630 lysis buffer 
The lysis buffer was prepared by adding 3% IGEPAL CA-630 
((Octylphenoxy) polyethoxyethanol) (Sigma, Cat. No. 13021) and 20 mM 
EDTA to 50 mM Tris[hydroxymethyl]aminomethane (Tris) (USB, Cat. No. 
75825). It was adjusted to pH 7.5 by 1 M HCl or NaOH. The buffer was 
stored at room temperature before use. 
(2) Sodium dodecvl sulphate (SDS) 
SDS powder (USB, Cat. No. 75819) was dissolved in deionized water to 
give 5% (w/v) SDS solution. It was stored at room temperature before use. 
(3) TinE^ buffer 
The buffer containing 10 mM Tris and 0.1 mM EDTA in deionized water 
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was adjusted to pH 7.5 by 1 M HCl or NaOH. It was stored at room 
temperature before use. 
(4) RNaseA 
RNase A powder (USB, Cat No. 78020), isolated from bovine pancreas and 
possessing a concentration of 96.4 units/mg, was dissolved in TioEo.i buffer 
to give a stock solution of 10 |ig/}xL. It was stored as 500 \\L aliquots at 
-20�C before use. 
(5) Proteinase K 
Proteinase K powder (USB, Cat. No. 76230), isolated from Tritirachium 
album and possessing a specific activity of 50 units/mg, was dissolved in 
TioEo.i buffer to give a stock solution of 20 jig/jiL. It was stored as 500 jiL 
aliquots at -20''C before use. 
(6) Sodium acetate (NaOAc) 
The 3 M NaOAc solution was prepared by suspending 24.61 g NaOAc 
powder (Sigma, Cat No. S5636) in 100 mL deionized water. It was then 
sterilized by autoclaving at \2VC for 20 minutes and stored at room 
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temperature before use. 
2.1.3.9 Reagents and buffers for DNA agarose gel electrophoresis 
(1) Tris-borate-EDTA (TBE) buffer 
The 5X TBE buffer was prepared by suspending 54 g Tris, 27.5 g boric acid 
(USB, Cat No. 76324) and 20 mL 5 M EDTA in 1 litre deionized water. 
The solution was then adjusted to pH 8.0. The working concentration of 
0.5X TBE buffer was prepared by diluting the 5X stock solution with 
deionized water. Both the stock and working solutions were kept at 4°C 
before use. 
(2) Gel loading solution 
The 5X gel loading solution (Sigma, Cat. No. G2526), containing 0.05% 
(w/v) bromophenol blue, 40% (w/v) sucrose, 0.1 M EDTA (pH 8.0) and 
0.5% (w/v) SDS, was used for non-denaturing agarose gel electrophoresis 
of nucleic acids. The solution was stored at room temperature before use. 
One volume of the gel loading solution was mixed with four volumes of 
DNA samples before loading into the wells of the agarose gel. 
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(3) 100 bp DNA ladder 
The 100 bp DNA ladder (Invitrogen, Cat. No. 15628-050), with a 
concentration of 1 |xg/jiL, contains 15 blunt-ended fragments ranging from 
100 to 1500 bp in multiples of 100 bp and an extra fragment at 2072 bp. It 
was stored at -20°C before use. The working concentration of 0.1 ^g/jiL was 
prepared by diluting the stock solution to 10 fold with TioEo.i buffer. 
(4) Agarose gel 
The 2% agarose gel was prepared by dissolving 20 g agarose low 
electroendosmosis (LE) powder (USB, Cat. No. 32802) in 1 litre 0.5X TBE 
buffer. The solution was heated at 70°C with continuous stirring to facilitate 
the dissolution until the solution became clear. It was stored in a closed 
container at room temperature until use. The solidified agarose gel was 
melted by heating in a microwave oven before use. 
(5) Ethidium bromide (EtBr) 
EtBr powder (Sigma, Cat. No. E7637) was dissolved in deionized water to 
give a 10 mg/mL stock solution. The working solution of 1 |ig/mL was 
prepared by diluting the stock solution to 10,000 fold with deionized water. 
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Both the stock and working solutions were stored in dark at room 
temperature. 
2.1.3.10 Reagents and buffers for Cell Death ELISA 
(1) Cell Death Detection ELISA^^^^ Kit 
The Cell Death Detection ELISA^lus Kit (Roche, Cat. No. 11774425001) 
consists of anti-histone-biotin antibody, anti-DNA-POD antibody, positive 
control, incubation buffer, lysis buffer, substrate buffer, ABTS substrate 
tablets, streptavidin-coated microplates, and adhesive cover foils. It was 
used for the in vitro determination of cytoplasmic histone-associated DNA 
fragments quantitatively and qualitatively after cell death induction. It was 
stored at 4°C until use. 
(2) Immunoreagent 
The immunoreagent was freshly prepared by mixing one volume of 
anti-histone biotin antibody, one volume of anti-DNA-POD antibody and 18 
volumes of incubation buffer. 
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2.1.3.11 Reagents and buffers for measuring caspase activity 
(1) Cell lysis buffer 
The lysis buffer contains 1% IGEPAL CA-630, 150 mM NaCl (USB, Cat. 
No. 21618), 50 mM Tris, 1 mM EDTA and one tablet of complete protease 
inhibitor cocktail (Roche, Cat No. 11697498001) in 50 mL deionized water. 
The buffer was then adjusted to pH 7.5 by 1 M HCl or NaOH. It was stored 
at 4GC before use. 
(2) Dithiothreitol (DTT) 
DTT powder (USB, Cat. No. 15397) was dissolved in deionized water to 
give a 1 M stock solution. It was added to the 2X reaction buffer to a final 
concentration of 10 mM to stabilize the enzymes with free sulfhydryl 
groups for supporting full enzymatic activities. The DTT stock solution was 
stored at -20''C before use. 
(3) Bovine serum albumin (BSA) 
BSA powder (Sigma, Cat. No. A9647) was dissolved in sterilized deionized 
water to give 2 mg/mL and 10 mg/mL stock solutions. The 2 mg/mL BSA 
stock solution was used for the construction of protein standard curve for 
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quantification of protein concentration. The 10 mg/mL BSA stock solution 
was added to the 2X reaction buffer to a final concentration of 100 }ig/mL. 
Both stock solutions were stored at -20°C before use. 
(4) Reaction buffer 
The 2X reaction buffer contains 20 mM HEPES (USB, Cat. No. USB 
16926)-KOH (Sigma, Cat. No. PI 767) (pH 7.0), 80 mM 
p-glycerophosphate (Sigma, Cat. No. G6251), 100 mM NaCl, 4 mM MgC^ 
(Sigma, Cat. No. M8266), 10 mM EGTA (Sigma, Cat. No. E4378) and 0.2% 
3,3-cholamidopropyl- dimethylanommonio-1 -propane sulfonate (CHAPS) 
(USB, Cat. No. 13361). The solution was kept at 4°C until use. DTT and 
BSA were added to the 2X reaction buffer to a final concentration of 10 mM 
and 100 jig/mL respectively right before use. 
(5) Bradford reagent 
The Bradford reagent (Sigma, Cat. No. B6916) is a 2X solution. During the 
quantification of protein concentration, one volume of Bradford reagent was 
mixed with one volume of protein sample. The Bradford reagent was stored 
in dark at 4�C before use. 
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(6) Caspase inhibitors, substrates and calibrator 
(a) Caspase-3 inhibitor, Ac-DEVD-CHO 
Acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-CHO) powder (Alexis, 
Cat. No. ALX-260-030) was dissolved in DMSO to give a 10 mM stock 
solution. It is a specific reversible inhibitor of caspase-3. The stock 
solution was stored as 50 |iL aliquots in dark at -20''C before use. 
(b) Caspase-3 substrate, Ac-DEVD-AMC 
Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) 
powder (Sigma, Cat. No. A1086) was dissolved in DMSO to give a 2 
mM stock solution. It is a fluorogenic substrate of caspase-3. The stock 
solution was stored as 50 |iL aliquots in dark at -20°C before use. 
(c) Caspase-8 inhibitor. Ac-IETD-CHO 
Acetyl-Ile-Glu-Thr-Asp-aldehyde (Ac-IETD-CHO) powder (Alexis, Cat. 
No. ALX-260-043) was dissolved in DMSO to give a 10 mM stock 
solution. It is a reversible inhibitor of caspase-6, -8 and granzyme B. 
The stock solution was stored as 50 jiL aliquots in dark at -20°C before 
use. 
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(d) Caspase-8 substrate, AoIETD-AMC 
Acetyl-Ile-Glu-Thr-Asp-7-amido-4-methylcoumarin (Ac-IETD-AMC) 
powder (Alexis, Cat. No. ALX-260-042) was dissolved in DMSO to 
give a 1 mM stock solution. It is a fluorogenic substrate of caspase-6, -8 
and granzyme B. The stock solution was stored as 50 pL aliquots in dark 
at -20°C before use. 
(e) Caspase-9 inhibitor, Ac-LEHD-CHO 
Acetyl-Leu-Glu-His-Asp-aldehyde (Ac-LEHD-CHO) powder (Alexis, 
Cat. No. ALX-260-079) was dissolved in DMSO to give a 10 mM stock 
solution. It is a reversible inhibitor of caspase-9 and related cysteine 
proteases. The stock solution was stored as 50 |iL aliquots in dark at 
-20°C before use. 
(f) Caspase-9 substrate. Ac-LEHD-AMC 
Acetyl-Leu-Glu-His-Asp-7-amido-4-methylcoumarin (Ac-LEHD-AMC) 
powder (Alexis, Cat. No. ALX-260-080) was dissolved in DMSO to 
give a 1 mM stock solution. It is a fluorogenic substrate of caspase-9 
and related cysteine proteases. The stock solution was stored as 50 \\L 
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aliquots in dark at - 2 0 � � b e f o r e use. 
(g) Pan-caspase inhibitor, Z-VAD-FMK 
Z-Val-Ala-Asp(OMe)-fluoromethylketone (Z-VAD-FMK) powder 
(Alexis, Cat. No. ALX-260-039) was dissolved in DMSO to give a 10 
mM stock solution. It is an irreversible and cell permeable 
broad-spectrum caspase inhibitor. The stock solution was stored as 50 
jiL aliquots in dark at before use. 
(h) 7-amino-4-methvlcoumarin (AMC) 
AMC powder (Sigma, Cat. No. A9891) was dissolved in DMSO to give 
a 50 mM stock solution. It was used as a standard calibrator for the 
quantification of caspase-3, -8 and -9 activities. The solution was stored 
in dark at 4°C before use. 
2.1.3.12 Reagents and buffers for Western blotting 
(1) Cell lysis buffer for whole cell protein isolation 
The lysis buffer contains 1% IGEPAL CA-630, 150 mM NaCl, 50 mM Tris, 
1 mM EDTA and one tablet of complete protease inhibitor cocktail in 50 mL 
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deionized water. The buffer was then adjusted to pH 7.5 by 1 M H Q or 
NaOH. It was stored at 4°C before use. 
(2) Cell lysis buffer for cytosolic protein isolation 
The lysis buffer contains 75 mM NaCl, 1 mM NaHaPO* (Sigma, Cat. No. 
S0751), 8 mM NaiHPO* (Sigma, Cat. No. S0876), 250 mM sucrose (Sigma, 
Cat. No. S0389), complete protease inhibitor cocktail and 0.5 |ig/|iL 
digitonin (Sigma, Cat. No. D141). The buffer was freshly prepared before 
use. 
(3) Cell lysis buffer for mitochondrial protein isolation 
The lysis buffer contains 75 mM NaCl, 1 mM NaHbPO*, 8 mM Na2HP04, 
250 mM sucrose, complete protease inhibitor cocktail and 8 jig/jiL digitonin. 
The buffer was freshly prepared before use. 
(4) Bradford reagent 
The Bradford reagent is a 2X solution. During the quantification of protein 
concentration, one volume of Bradford reagent was mixed with one volume 
of protein sample. The Bradford reagent was stored in dark at 4°C before 
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use. 
(5) Bovine serum albumin (BSA) 
BSA powder was dissolved in sterilized deionized water to give a 2 mg/mL 
stock solution. It was used for the quantification of protein concentration by 
dilution to 2 - 10 fxg/mL with deionized water for the construction of protein 
standard curve. The BSA stock solution was stored at -20°C before use. 
(6) Lower buffer for separating gel 
Tris powder (USB, Cat. No. 75825) was dissolved in deionized water to 
give a 1.5 M lower buffer. The buffer was then adjusted to pH 8.8 by 1 M 
HCl or NaOH. It was stored at 4°C before use. 
(7) Upper buffer for stacking gel 
Tris powder (USB, Cat. No. 75825) was dissolved in deionized water to 
give a 0.5 M upper buffer. The buffer was then adjusted to pH 6.8 by 1 M 
HCl or NaOH. It was stored at 4°C before use. 
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(8) Sodium dodecyl sulphate (SDS) 
SDS powder (USB, Cat. No. 75819) was dissolved in deionized water to 
give a 10% (w/v) SDS solution. It was stored at room temperature before 
use. 
(9) Acrylamide/bis-acrylamide solution 
The acrylamide: N,N' -methylene-bis-acrylamide electrophoresis purity 
reagent (Bio-Rad, Cat. No. 161-0158) contains 30% (w/v) stock solution of 
acrylamide (146.1 g) and N,N'-methylene-bis-acrylamide (3.9 g) at a total 
monomer to crosslinker ratio of 37.5:1. It was stored in dark at 4°C before 
use. 
(10) Ammonium persulfate (APS) 
APS powder (Bio-Rad, Cat. No. 161-0700) was dissolved in deionized 
water to give a 10% (w/v) APS solution. It was stored as 500 jiL aliquots at 
-20�C. 
(11) N.N.N\N^-Tetra-methYlethvlenediamine(TEMED) 
TEMED solution (Bio-Rad, Cat. No. 161-0800) was stored in dark at 4°C 
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before use. 
(12) Sample loading buffer 
The 4X sample loading buffer was prepared by adding 0.4 mL 0.05% (w/v) 
bromophenol blue, 2 mL upper buffer, 2 mL glycerol, 2 mL 10% SDS and 
0.2 mL 2-mercaptoethanol (Sigma, Cat. No. M7154) to 1.4 mL deionized 
water. The buffer was stored in dark at 4°C before use. 
(13) Novex® Sharp pre-stained protein standard 
The ready-to-use protein standard (Invitrogen, Cat. No. LC5800) contains 
12 pre-stained protein bands with molecular mass ranging from 3.5 to 260 
kDa. It was prepared in a loading buffer with 65 mM Tris (pH 6.5), 30% 
glycerol, 2% SDS and 2.5 mM EDTA. The protein standard was stored at 
-20�C before use. 
(14) SDS running buffer 
The lOX SDS running buffer consists of 250 mM Tris, 1.92 M glycine 
(USB, Cat. No. 16407) and 1% SDS in deionized water. The solution was 
then adjusted to pH 8.6. The IX running buffer was prepared by diluting the 
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lOX stock solution with deionized water. Both the stock and working 
solutions were kept at 4°C before use. 
(15) Transfer buffer 
The lOX transfer buffer contains 250 mM Tris, 1.92 M glycine in deionized 
water. The solution was then adjusted to pH 8.6. The IX transfer buffer was 
prepared by diluting 40 mL lOX stock solution with 360 mL deionized 
water and 100 mL methanol (Scharlau, Cat. No. ME0316). Both the stock 
and working solutions were kept at 4 � � b e f o r e use. 
(16) Polyvinylidene fluoride (PVDF) transfer membrane 
Immobilon-P transfer membrane (Millipore, Cat. No. IPVHOOOlO) with 
pore size of 0.45 [im was cut into 8.5 cm x 5.5 cm transfer membranes and 
stored at room temperature before use. 
(17) Filter paper 
Whatman chromatography paper (Whatman, Cat. No. 3030-917) with 
thickness of 0.34 mm was used as transfer filter paper. It was cut into 8.5 
cm X 5.5 cm and stored at room temperature before use. 
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(18) Washing buffer 
The lOX Tris-buffered saline-Tween-20 (TBS-T) buffer contains 100 mM 
Tris, 1 M NaCl and 1% Tween-20 (Sigma, Cat. No. P2287) in deionized 
water. The solution was then adjusted to pH 7.5. The IX washing buffer was 
prepared by diluting the lOX stock solution with deionized water. Both the 
stock and working solutions were kept at 4°C before use. 
(19) Non-fat milk solution 
The 5% (w/v) non-fat milk solution was prepared by suspending 0.25 g 
non-fat milk powder (Nestle) in 5 mL washing buffer for each membrane. It 
was used as the blocking solution and freshly prepared each time. 
(20) Primary and secondary antibodies 
The primary and secondary antibodies used for Western blotting were listed 
in Table 2.1. For the primary antibodies, anti-AIF, anti-cdk2 and anti-cyclin 
E antibodies were stored at 4�C while anti-P-actin, anti-cdk4 and anti-cdk6 
antibodies were kept at -20°C. All the secondary antibodies were stored at 
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Table 2.1. Primary and secondary antibodies used for Western 
blotting experiments. 
Antibody Source Brand 
Anti-AIF Mouse Santa Cruz, Cat. No. 13116 
Anti-P-actin Mouse Sigma, Cat. No. A5316 
Anti-cdk2 Mouse Santa Cruz, Cat. No. 6248 
Primary Cell Signaling, Cat. No. 
Anti-cdk4 Mouse 
antibodies 2906 
Cell Signaling, Cat. No. 
Anti-cdk6 Mouse 
3136 
Anti-cyclin E Rabbit Santa Cruz, Cat. No. 481 
HRP-linked Amersham, Cat. No. 
Sheep 
Secondary anti-mouse IgG NA931 
antibodies HRP-linked Amersham, Cat. No. 
Donkey 
anti-rabbit IgG NA934 
(21) Western blotting luminal reagent 
The Western blotting luminal reagent (Santa Cruz, Cat. No. sc-2048) 
consists of solution A and solution B. The two solutions were mixed at a 
ratio of 1:1 just before use. They were stored in dark at 4°C until use. 
(22) X-ray films 
Fuji Super RX Medical X-ray films (Fujifilm, Cat. No. 15865651-1) were 
stored in dark at before use. 
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2.1.3.13 Reagents for determining nitric oxide production 
(1) Sodium nitrite (NaNO?) 
Sodium nitrite powder (Sigma, Cat. No. S2252) was dissolved in complete 
RPMI medium to give a 1 M NaNOi stock solution. It was freshly prepared 
and used for the quantification of nitric oxide production by dilution to 1.56 
to 100 jiM with complete RPMI medium for the construction of NaNOi 
standard curve. 
(2) Griess reagent 
Griess reagent contains 0.5% sulfanilamide (Sigma, Cat. No. S9251) and 
0.05% N-( 1 -naphthyl)ethylenediamine dihydrochloride (Sigma, Cat. No. 
N5889) in 2.5% H3PO4. It was freshly prepared and stored in dark at 4°C 
until use. 
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2.2 Methods 
2.2.1 Culture of tumor cell lines 
Tumor cell lines were cultured in tissue culture flasks. The murine leukemia 
WEHI-3B JCS and PU5-1.8 cells were maintained in complete RPMI 
medium which contains 10% FBS and 1% PSF while the human leukemia 
HL-60 cells were maintained in complete RPMI medium supplemented with 
20% FBS and 1% PSF. They were incubated at 37°C in a humidified 
incubator with 5% carbon dioxide (CO2). 
On the day of subculture, cells were collected by centrifugation at 600 x g at 
for 3 minutes. After resuspending in complete medium, an appropriate 
amount of ceil suspension was then passed to a new culture flask with fresh 
complete medium. Cells in the exponential growth phase were used for 
assays. For long term storage, cells were maintained in cryopreservation vial 
with medium containing 50% FBS, 40% RPMI and 10% DMSO and placed 
in liquid nitrogen for cryopreservation. 
2.2.2 Isolation, preparation and culture of murine peritoneal macrophages 
BALB/c mice were injected intraperitoneally (i.p.) with 3% thioglycollate 
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broth (1.5 mL/mouse) using a 3 mL syringe fitted with a 25 gauge x Vg" 
needle to induce macrophage migration into the peritoneal cavity. After 
three days, the mice were sacrificed by cervical dislocation and placed on a 
clean surface with their ventral side up. The abdominal skin was cleaned 
with 70% ethanol. A small hole was cut from the skin and the skin was torn 
apart until the abdominal wall was exposed. Next, 3 mL plain RPMI 
medium and an equal volume of air were injected into the peritoneal cavity 
using a 5 mL syringe fitted with a 20 gauge x 1V2" needle to wash and 
inflate it. The peritoneal cavity was washed three times in order to rinse out 
the peritoneal exudate cells (PECs). The cells were then incubated with 
ACK buffer at room temperature for 10 minutes to lyse the contaminating 
red blood cells. After centrifugation, the thioglycollate-elicited PECs were 
resuspended in complete RPMI medium for further use. To obtain the 
peritoneal macrophages from PECs, the cells were incubated at 37°C for 3 
hours in a humidified incubator with 5% CO2 supply to allow the 
attachment of peritoneal macrophages to 96-well plates and the 
non-adherent cells were removed by washing three times with warm plain 
RPMI medium. 
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2.2.3 Cell proliferation and cytotoxicity studies 
(1) MTT reduction assay 
The murine myelomonocytic leukemia WEHI-3B JCS cells (2 x 
cells/mL), human promyelocytic leukemia HL-60 cells (1 x 10^  cells/mL), 
murine macrophage-like leukemia PU5-1.8 cells (2 x cells/mL) and 
murine peritoneal exudate cells (1 x 10^ cells/mL) were cultured with 
solvent control or different concentrations of statins in 96-well plates and 
incubated at 37°C for 24, 48 or 72 hours in a humidified incubator with 5% 
CO2 supply. After the defined incubation time, 30 jjL 4 mg/mL MTT 
solution was added to the wells and the cells were incubated at 37°C for 
further 2 to 4 hours depending on the cell type. After centrifugation at 300 x 
g at 4°C for 10 minutes, the medium was removed and 50 |iL DMSO was 
then added. Cell growth and viability can be determined by measuring the 
absorbance at 540 nm using a microplate reader (Bio-Rad, Benchmark 
microplate reader). The inhibition of cell growth was calculated as follows: 
… 1 .1 . . Abs540 of control - Abs540 of sample , . 
% inhibition = xlOO% 
Abs 540 of control 
(2) ^H-TdR incorporation assay 
Murine leukemia WEHI-3B JCS cells (2 x lO* cells/mL) were cultured with 
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solvent control or different concentrations of fluvastatin in 96-well plates 
and incubated at 37®C for 24, 48 or 72 hours in a humidified incubator with 
5% CO2 supply. After the defined incubation time, the cells were pulsed 
with 0.5 \iCi ^H-TdR in 20 |iL complete RPMI medium at 37�C for 6 hours 
and then frozen at -20°C overnight. After thawing at SV'C, the cells were 
harvested onto glass microfiber filter (PerkinElmer, Cat. No. 6005174) by a 
cell harvester (Packard, Filtermate 96 cell harvester). The radioactivity, 
expressed in counts per minute (cpm), was measured using a microplate 
scintillation counter (Packard, Topcount NXT microplate scintillation and 
luminescence counter). The inhibition of ^H-TdR incorporation was 
calculated as follows: 
0/0 inhibition = cpm of control - cpm of sample ^ 丄驟。 
cpm of control 
(3) Trypan blue exclusion assay 
Cell viability can be determined by trypan blue exclusion assay based on the 
integrity of cell membrane. By observing under microscope, viable cells 
excluded the dye while dead cells were stained blue. Murine leukemia 
WEHI-3B JCS cells (2 x lO* cells/mL) were incubated with solvent control 
or different concentrations of fluvastatin at 37°C for 24, 48 or 72 hours in a 
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humidified incubator with 5% CO2 supply. After the defined incubation 
time, the cells were collected and the cell number and viability were 
examined by a cell viability analyzer (Beckman Coulter, Vi-CELL XR cell 
viability analyzer). 
2.2.4 In vivo tumorigenicity study 
Murine leukemia WEHI-3B JCS cells (2 x lO* cells/mL) were incubated 
with solvent control or different concentrations of fluvastatin at 37°C for 20 
hours in a humidified incubator with 5% CO2 supply. After centrifugation at 
600 X g at 4°C for 3 minutes, the cells were collected, washed with plain 
RPMI medium and resuspended in complete RPMI medium. WEHI-3B JCS 
cells (1 X 10^  cells in 500 jiL complete RPMI medium) were injected 
intraperitoneally using a 1 mL syringe fitted with a 25 gauge x %’，needle 
into each BALB/c mouse in groups of five. After 10 days, the mice were 
sacrificed and the leukemia WEHI-3B JCS cells were collected from the 
peritoneal cavity of the mice. The number of viable leukemia cells was then 
counted by the Vi-CELL XR cell viability analyzer. 
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2.2.5 Cell cycle profile and flow cytometric analysis 
Murine leukemia WEHI-3B JCS cells (2 x celis/mL) were incubated 
with plain RPMI medium at 3TC for 24 hours in a humidified incubator 
with 5% CO2 supply to synchronize the cells by serum starvation. They 
were then cultured with solvent control or different concentrations of 
fluvastatin at 37°C for a defined incubation time. After centrifugation at 600 
X g at 4�C for 3 minutes, the cells were collected, washed with PBS, and 
fixed with 1 mL 70% ethanol at 4�C for 30 minutes. The cells were 
centrifuged at 400 x g at 4�C for 10 minutes, washed with PBS and 
centrifuged again at 400 x g at 4�C for 10 minutes to remove the fixative. 
Afterwards, the cells were resuspended in 1 mL freshly prepared PI DNA 
staining buffer and incubated in dark at 3TC for 30 minutes. The stained 
cells were then analyzed using a flow cytometer (BD Biosciences, 
FACSCanto) with the FACSDiva software (BD Biosciences) to measure the 
DNA content. The cell cycle distribution patterns in the Gq/Gi, S and G2/M 
phases were calculated by the ModFit LT software (Verity Software House). 
2.2.6 Hoechst staining 
Murine leukemia WEHI-3B JCS cells (2 x 10^  cells/mL) were incubated 
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with solvent control or different concentrations of fluvastatin at �^TC for 48 
hours in a humidified incubator with 5% CO2 supply. After centrifUgation at 
600 X g at 40c for 3 minutes, the cells were collected and washed with PBS. 
The cells were then fixed onto clean microscopic glass slides by 
centrifugation at 500 rpm for 5 minutes using a cytocentrifuge (Shandon, 
Cytospin 3 cytocentrifuge). The cells were air-dried and fixed with 2% 
paraformaldehyde for 20 minutes. After washing with deionized water, the 
cells were stained with Hoechst 33342 and observed under a fluorescence 
microscope (Nikon, TE2000). 
2.2.7 DNA fragmentation analysis 
Murine leukemia WEHI-3B JCS cells (2 x 10^ cells/mL) were incubated 
with solvent control or different concentrations of fluvastatin at 3TC for 24 
or 48 hours in a humidified incubator with 5% CO2 supply. After 
centrifugation at 600 x g at 4�C for 3 minutes, WEHI-3B JCS cells (2 x 10^  
cells) were collected, washed with PBS and incubated with IGEPAL 
CA-630 lysis buffer at 37�C for 10 minutes. After centrifugation at 6,000 x 
g at 40c for 5 minutes, the supernatant containing DNA fragments was 
collected and 50 |iL 5% SDS was added to each sample. Next, 10 \xL RNase 
7 0 
Chapter 2 Materials and Methods 
A was added and the samples were incubated at 56�C for 1.5 hours to 
remove the cellular RNA. Afterwards, 20 |aL proteinase K was added and 
the samples were incubated at 56°C for further 1.5 hours to remove the 
proteins present. The DNA was then precipitated by adding 30 pL 3 M 
NaOAc and 750 iiiL 100% ethanoL After centriftigation at 20,800 x g at 4�C 
for 30 minutes, the DNA pellets were washed with 70% ethanol followed by 
100% ethanol. The DNA pellets were then air-dried, resuspended in TioEo.i 
buffer and incubated at 3TC for 30 minutes. The DNA samples were then 
heated at 65°C for 5 minutes. After mixing with 5 pJL gel loading solution, 
the DNA samples with a final volume of 25 fiL were loaded into the wells of 
2% agarose gel for electrophoresis at a constant voltage of 100 V. After 
electrophoresis, the gel was stained with EtBr for 3 minutes and destained 
with deionized water for 10 minutes. DNA bands were observed under UV 
illumination by a UV transilluminator (Bio-Rad, Gel Doc 2000 gel 
documentation system). 
2.2.8 Cell Death ELISA 
Cell Death ELISA was performed based on the manufacturers' protocol. 
Briefly, murine leukemia WEHI-3B JCS cells (2 x 10^  cells/mL) were 
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cultured with solvent control or different concentrations of fluvastatin in 
96-well plates and incubated at 37°C for 24 hours in a humidified incubator 
with 5% CO2 supply. After centrifugation at 300 x g at 4°C for 10 minutes, 
the medium was removed and the cells were incubated with lysis buffer at 
room temperature for 30 minutes. After centrifugation at 300 x g at 4°C for 
10 minutes, 20 jiL supernatant was transferred into streptavidin-coated wells 
of the microplate strips. Next, 80 |iL freshly prepared immunoreagent was 
added to the wells. The microplate was incubated at room temperature for 2 
hours. After washing three times with incubation buffer, 100 \xL ABTS 
substrate solution, prepared by dissolving 1 tablet of substrate in 5 mL 
substrate buffer, was added to the wells and the microplate was incubated at 
room temperature in dark for 15 minutes for colour development. The 
absorbance was measured at 405 nm with reference wavelength at 490 nm 
using the Benchmark microplate reader. The enrichment factor of 
nucleosomes in cell lysates was calculated as follows: 
” .1 p Abs405 of sample …八 
Enrichment factor 二 xlOO% 
Abs405 of control 
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2.2.9 Mitochondrial membrane potential analysis 
Murine leukemia WEHI-3B JCS cells (2 x lo* cells/mL) were incubated 
with solvent control or different concentrations of fluvastatin at 3TC for 24, 
36 or 48 hours in a humidified incubator with 5% CO2 supply. After 
centrifugation at 600 x g at 4 T for 3 minutes, WEHI-3B JCS cells (1 x 10^ 
cells) were collected and washed with PBS. The cells were then 
resuspended in 1 mL JC-1 staining solution prepared by mixing 1.3 jiL 5 
mg/mL JC-1 stock solution with 1 mL PBS. The cells were incubated in 
dark at 3 7 � � f o r 15 minutes. The stained cells were then analyzed using the 
FACSCanto flow cytometer. The percentage of cells with a change in 
mitochondrial membrane potential was calculated by the WinMDI software 
(The Scripps Research Institute). 
2.2.10 Measurement of caspase activity 
(1) Cell treatment and protein extraction 
Murine leukemia WEHI-3B JCS cells (2 x cells/mL) were cultured with 
solvent control or different concentrations of fluvastatin at YFC for 48 
hours in a humidified incubator with 5% CO2 supply. After centrifugation at 
600 X g at 4°C for 3 minutes, the cells were collected, washed with PBS and 
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incubated with cell lysis buffer (50 [iL for 1 x 10^  cells) at 4°C for 10 
minutes. The cell lysate was vortexed vigorously and centrifuged at 20,800 
X g at 40c for 3 minutes. The supernatant containing caspases was then 
collected. 
(2) Quantification of protein concentration 
The supernatant was subjected to Bradford protein assay to determine the 
concentration of protein present. BSA standard solutions of 2 to 10 jig/niL 
were prepared by diluting the 2 mg/mL BSA stock solution with deionized 
water. After diluting 1 JLIL protein samples with 1 mL deionized water, 500 
jiL diluted protein samples were mixed with an equal volume of Bradford 
reagent. The absorbance at 595 nm was measured using the BioPhotometer 
(Eppendorf) and the protein concentration was calculated from the protein 
standard curve. 
(3) Fluorometric measurement of caspase activity 
The protein samples were diluted to 1 Afterwards, 50 jiL diluted 
protein samples were mixed with an equal volume of 2X reaction buffer 
while 50 |xL diluted protein samples, 50 jiL 2X reaction buffer and 1 \xL 
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caspase inhibitor were mixed together as a control to ensure that the 
fluorescence signal detected would be due to the caspase activities. Samples 
without inhibitor were incubated in dark at 4®C for 30 minutes while the 
controls with inhibitor were incubated in dark at 3TC for 30 minutes. All 
samples were then added with caspase substrates with a final concentration 
of 10 jiM and incubated in dark at 37�C for 1 hour. The fluorescence signal 
was measured with excitation at 360 nm and emission at 465 run using a 
fluorescence plate reader (Tecan, Polarion fluorescence plate reader). The 
fluorescence reading was then converted to AMC release, expressed in 
relative fluorescence unit (RFU), from the AMC standard curve generated 
by diluting the AMC stock solution to AMC standard solutions of 0.078 to 5 
pM. 
2.2.11 Protein expression study 
(1) Cell treatment and protein extraction 
Murine leukemia WEHI-3B JCS cells (2 x lO* cells/mL) were cultured with 
solvent control or different concentrations of fluvastatin at 37°C for 48 
hours in a humidified incubator with 5% CO2 supply. After centrifiigation at 
600 X g at 4°C for 3 minutes, the cells were collected and washed with PBS. 
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(a) Isolation of whole cell protein 
The cells were incubated with cell lysis buffer (50 |iL for 1 x 10^ cells) 
at 40c for 10 minutes. The cell lysate was vortexed vigorously and 
centrifuged at 20,800 x g at 4°C for 5 minutes. The protein-containing 
supernatant was then collected. 
(b) Isolation of cytosolic and mitochondrial protein 
The cells were first resuspended in cell lysis buffer for cytosolic protein 
isolation (50 jiL for 4 x 10 cells), vortexed vigorously for 30 seconds 
and centrifuged at 10,600 x g at A^ 'C for 1 minute. The supernatant 
containing cytosolic protein was collected. The cell pellet was then 
resuspended in cell lysis buffer for mitochondrial protein isolation (50 
}iL for 4 X 10^  cells), vortexed vigorously for 30 seconds and 
centrifuged at 10,600 x g at 4°C for 1 minute. The supernatant 
containing mitochondrial protein was collected. 
(2) Quantification of protein concentration 
The protein samples were subjected to Bradford protein assay to determine 
the concentration of protein present. BSA standard solutions of 2 to 10 
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|ig/mL were prepared by diluting the 2 mg/mL BSA stock solution with 
deionized water. After diluting 1 |iL protein samples with 1 mL deionized 
water, 500 \iL diluted protein samples were mixed with an equal volume of 
Bradford reagent. The absorbance at 595 nm was measured using the 
BioPhotometer (Eppendorf) and the protein concentration was calculated 
from the protein standard curve. 
(3) SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was applied to separate proteins according to their molecular 
sizes. A polyacrylamide gel was composed of a lower separating gel and an 
upper stacking gel. A larger volume of acrylamide was added to the 
separating gel for a smaller size of protein under investigation, while a fixed 
acrylamide concentration was employed for the stacking gel. The 
composition of the separating and stacking gels was shown in Table 2.2. 
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Table 2.2. The composition of separating and stacking gels in 
SDS-PAGE. 
Separating gel (5 mL) Stacking gel (3 mL) 
Gel percentage “ 10% 12% ^ 
Deionized water 2 mL 1.65 mL 1.65 mL 
Lower buffer 1.25 mL 1.25 mL ---
Upper buffer --- --- 0.75 mL 
10% SDS 25 |iL 25 [iL 30 [iL 
10% APS 75 ^L 75 ^L 40 ^ iL 
TEMED 2 ^L 2 [iL 3 jiL 
Acrylamide/bis stock 1.67 mL 2 mL 0.5 mL 
Protein samples (20 jig) were first mixed with sample loading buffer and 
boiled for 5 minutes. The samples and the protein standard were then loaded 
into the wells of the SDS-polyacrylamide gel for electrophoresis at a 
constant voltage of 100 V. 
(4) Semi-dry transfer of protein to PVDF membrane 
Six pieces of filter papers were immersed in transfer buffer while the PVDF 
transfer membrane was activated with 100% methanol. Three wet filter 
papers were first placed on the semi-dry electroblotter (Bio-Rad, Trans-Blot 
SD semi-dry electrophoretic transfer cell) and the transfer membrane was 
then placed on top. The separating gel from SDS-PAGE was washed with 
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deionized water and placed on the transfer membrane, followed by the other 
three wet filter papers on top. Air bubbles between the layers were removed 
by rolling a glass rod on the filter paper at the top. Electroblotting was then 
performed by applying a constant voltage of 16 V for 45 minutes. 
(5) Enhanced chemiluminescence (ECL) detection 
After electroblotting, the membrane was blocked with 5% non-fat milk 
solution and incubated at room temperature for 30 minutes with rotation to 
prevent non-specific binding of antibodies. Primary antibody against the 
target protein was then added to the milk solution at 1:1,000 dilution and the 
membrane was incubated at 4°C overnight with rotation. After washing with 
washing buffer for 5 minutes with rotation for three times, the membrane 
was probed with horseradish peroxidase-linked secondary antibody at 
1:1,000 dilution in washing buffer and incubated at room temperature for 1 
hour with rotation. After washing with washing buffer for 5 minutes with 
rotation for three times, the luminal reagent, prepared by mixing equal 
volumes of solutions A and B, was spread over the surface of the membrane. 
The membrane was then sandwiched with transparent plastic sheets and 
placed inside a film cassette. An X-ray film was placed over the sandwiched 
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membrane in a darkroom and the cassette was closed to allow exposure for 
varying time periods, ranging from 5 seconds to 3 minutes. The film was 
finally developed and fixed using an X-ray film processor (Kodak). The 
protein band intensities were quantified by the ImageJ software (National 
Institutes of Health). After normalization with the housekeeping protein 
3-actin, the relative intensities of the protein bands were compared with that 
of the solvent control. 
2.2.12 Cell morphological staining 
Murine leukemia WEHI-3B JCS cells (2,500 cells/mL) were incubated with 
solvent control or different concentrations of fluvastatin at 37°C for 72 
hours in a humidified incubator with 5% CO2 supply. After centrifugation at 
600 X g at 4�C for 3 minutes, WEHI-3B JCS cells (5 x 10^  cells) were 
collected, washed with PBS and fixed onto clean microscopic glass slides 
by centrifugation at 500 rpm for 5 minutes using the Shandon Cytospin 3 
cytocentrifUge. The cells were air-dried, fixed with Hemacolor® solutions 1 
for 15 seconds and washed with deionized water. The cells were then 
stained with Hemacolor� solution 2 for 15 seconds, washed with deionized 
water, stained with Hemacolor® solution 3 for 15 seconds and washed with 
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deionized water. The slides were finally mounted with the neutral mounting 
medium, Canada Balsam (Sigma, Cat. No. CI795). The cell morphology 
was observed under a light microscope (Zeiss, Axioskop II Plus light 
microscope). 
2.2.13 Cell size and granularity analysis by flow cytometry 
Murine leukemia WEHI-3B JCS cells (2 x lo"^  cells/mL) were incubated 
with solvent control or different concentrations of fluvastatin at 3TC for 72 
hours in a humidified incubator with 5% CO2 supply. After centrifugation at 
600 X g at 4�C for 3 minutes, WEHI-3B JCS cells (1 x 10^  cells) were 
collected, washed with PBS and resuspended in 1 mL PBS. The cells were 
then analyzed using the FACSCanto flow cytometer and the change in cell 
size and granularity was calculated by the FACSDiva software. 
2.2.14 Determination of nitric oxide production by macrophages 
Murine peritoneal exudate cells (1 x 10^  cells/mL) were cultured in 96-well 
plates and incubated at 37°C for 3 hours in a humidified incubator with 5% 
CO2 supply to allow the attachment of peritoneal macrophages to the wells. 
The wells were washed three times with plain RPMI medium to remove the 
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non-adherent peritoneal cells. The adherent macrophages were then 
incubated with solvent control or different concentrations of fluvastatin with 
20 ng/mL LPS at 37�C for 48 hours. After incubation, 100 jiL cell-free 
supernatant was transferred from each well into another 96-well microplate. 
Next, 1 0 0 JLIL freshly prepared Griess reagent was added to the wells and the 
microplate was incubated at room temperature in dark for 10 minutes for 
colour development. The absorbance was measured at 540 nm using the 
Benchmark microplate reader. The absorbance reading was then converted 
to NaNCh concentration based on the NaNO� standard curve generated by 
diluting the NaNO� stock solution to NaNO� standard solutions of 1.56 to 
100 \iM with complete RPMI medium. 
2.2.15 Statistical analysis 
Each experiment was repeated at least three times with consistent results. 
The results were expressed as arithmetic mean 士 standard error of the mean 
(SEM). Statistical significance between two groups of mean was determined 
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3.1 Introduction 
Statins are safe and effective drugs currently used for the treatment of 
hypercholesterolemia. They are inhibitors of HMG-CoA reductase, the 
rate-determining enzyme in cholesterol biosynthesis. They help to reduce the risk 
of cardiovascular diseases by their lipid-modifying properties as well as their 
cholesterol-independent effects. Among the pleiotropic activities of statins, their 
tumor suppressive effects are particularly of interest to us. Cholesterol 
metabolism is specifically active in malignant and rapidly proliferating cells. 
Thus, inhibition of cholesterol synthesis may help to reduce tumor cell growth 
(Sanchez-Martin et al., 2007). In fact, it has been demonstrated that statins 
possess anti-tumor effects on various types of tumors, including colon cancer, 
neuroblastoma, breast cancer and pancreatic cancer (Takahashi et al., 2007; 
Sassano et al., 2008). However, their modulatory effects and action mechanisms 
on myeloid leukemia cells remain poorly understood. 
In the present study, the anti-proliferative effect of various statins, including 
fluvastatin, simvastatin, lovastatin and pravastatin were first examined on the 
murine and human myeloid leukemia cell lines at different developmental stages. 
Based on the experimental results, fluvastatin and the murine myelomonocytic 
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leukemia WEHI-3B JCS cells were used for further investigation on the possible 
anti-leukemic action mechanisms of statins. The cytotoxicity of fluvastatin on 
WEHI-3B JCS cells as well as primary murine peritoneal macrophages were 
tested. The kinetics and reversibility of the anti-proliferative effect of fluvastatin 
on WEHI-3B JCS cells were examined. Attempts had been made to look into the 
relationship between the anti-proliferative effect of fluvastatin and the 
metabolites in the cholesterol biosynthesis pathway. In addition to in vitro studies, 
the effect of fluvastatin on the in vivo tumorigenicity of WEHI-3B JCS cells was 
investigated in syngeneic BALB/c mice. Furthermore, the cell cycle profile and 
the expression of cell cycle regulatory proteins in WEHI-3B JCS cells were 
examined after fluvastatin treatment in order to have a better understanding on 
the underlying mechanisms of the anti-proliferative effect of fluvastatin. 
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3.2 Results 
3.2.1 Anti-proliferative effect of statins on various murine and human 
myeloid leukemia cells 
A screening test on the effects of different statins on the proliferation of various 
myeloid leukemia cell lines was performed by the MTT reduction assay. The 
yellow MTT was reduced to insoluble formazan by mitochondrial dehydrogenase 
in viable cells. DMSO was then added to solubilize the formazan produced, 
which is directly proportional to the number of viable cell present (Mosmann, 
1983). The absorbance was measured spectrophotometrically at 540 nm. 
As shown in Figure 3.1, fluvastatin, simvastatin and lovastatin inhibited the 
growth of the murine myelomonocytic leukemia WEHI-3B JCS cells while 
pravastatin did not result in any significant growth-inhibitory effect at a 
concentration up to 50 jiM. Similar effects were observed for the three statins 
(fluvastatin, simvastatin and lovastatin) on the human promyelocytic leukemia 
HL-60 cells (Figure 3.2) and the murine macrophage-like tumor PU5-1.8 cells 
(Figure 3.3). The 50% inhibitory concentration (IC50) of different statins on 
various myeloid leukemia cell lines were estimated and summarized in Table 3.1. 
It was demonstrated that fluvastatin, simvastatin and lovastatin exhibited 
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growth-inhibitory effect on various myeloid cell lines to a different extent. 
Among the statins examined, fluvastatin was found to be the most potent drug as 
it resulted in the lowest IC50 value for all the three leukemia cell lines. Among 
the three cell lines employed, WEHI-3B JCS cells showed the highest sensitivity 
in drug response. In addition, WEHI-3B JCS cells were well-characterized and 
subcloned. They responded well to various differentiation inducers and can easily 
be transplanted into mice without rejection (Chan et al., 2009). Therefore, 
fluvastatin and the murine myelomonocytic leukemia WEHI-3B JCS cells were 
chosen as the drug and cell model for further mechanistic studies in this project. 
Furthermore, the solvent for fluvastatin, deionized water, was shown to possess 
no inhibitory effect on WEHI-3B JCS cell growth at concentrations up to 0.01% 
(equivalent to fluvastatin concentration up to 5 jaM) (Figure 3.4), implying that 
the observed growth-inhibitory effect of fluvastatin was resulted from the drug 
itself. 
8 7 
Chapter 3 A nti-Prol iferative Effect 
120-1 
1 � � -
[ 80- / Z � + Fluvastatin 
• 60- f / / " • “ Simvastatin 
Ic y X / Lovastatin 
•E 40- V / 
vP / M Pravastatin 
, , , , . 
^ 1 2 3 4 § 6 
2 0 � ^ 
Statin concentration (|liM) 
Figure 3.1. Growth-inhibitory effect of different statins on the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2 x 10^  
cells/mL) were incubated with solvent control or different concentrations of 
fluvastatin, simvastatin, lovastatin or pravastatin for 48 hours. Growth inhibition 
was then determined using MTT reduction assay as described in Chapter 2. 
Results were expressed as % inhibition of cell growth using solvent-treated cells 
as a control. Data shown represent mean 士 SEM of three independent 
experiments. 
8 8 




_ _ - I • • 
c 80-
.2 / Fluvastatin 
•芝 60- / 
~ J Simvastatin 
5 4 � - / 
04 t 1 1 1 1 1 
50 100 150 200 250 
-20」 




0 60- J 
1 40 ^ ^ 
- ^ ^ ^ -A- Lovastatin 
^ 20- ^ ^ 
0 - J ~ f 1 ~ I 1 1 1 
10 15 20 25 
- 2 0 」 * 
Statin concentration (jiM) 
Figure 3.2. Growth-inhibitory effect of different statins on the human 
promyelocytic leukemia HL-60 cells. HL-60 cells (1 x 10^  cells/mL) were 
incubated with solvent control or different concentrations of (A) fluvastatin, 
simvastatin or (B) lovastatin for 48 hours. Growth inhibition was then 
determined using MTT reduction assay as described in Chapter 2. Results were 
expressed as % inhibition of cell growth using solvent-treated cells as a control. 
Data shown represent mean 士 SEM of three independent experiments. 
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Figure 3.3. Growth-inhibitory effect of different statins on the murine 
macrophage-like tumor PU5-1.8 cells. PU5-1.8 cells (2 x cells/mL) were 
incubated with solvent control or different concentrations of fluvastatin, 
simvastatin or lovastatin for 48 hours. Growth inhibition was then determined 
using MTT reduction assay as described in Chapter 2. Results were expressed as 
% inhibition of cell growth using solvent-treated cells as a control. Data shown 
represent mean 士 SEM of three independent experiments. 
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Figure 3.4. Effect of solvent control (deionized water) on the growth of 
the murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS 
cells (2 X lo4 cells/mL) were incubated with different concentrations of solvent 
control (deionized water) for 48 hours. Growth inhibition was then determined 
using MTT reduction assay as described in Chapter 2. Results were expressed as 
% inhibition of cell growth using untreated cells as a control. Data shown 
represent mean 士 SEM of three independent experiments. 
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Table 3.1. The estimated IC50 of different statins on various myeloid 
leukemia cell lines. 
IC50 (^ M) at 48 h 
Statin for different myeloid leukemia cell lines 
WEHI-3B JCS HL-60 PU5-1.8 
Fluvastatin 1.0 ±0.01 15.2 ±0.75 1.6 ±0.26 
Simvastatin 1.7 土 0.08 16.9 ±0.75 2.7 ±0.60 
Lovastatin 1.3 土 0.04 17.2 士 2.00 6.8± 1.19 
Pravastatin ^ ^ N.D. 
Myeloid leukemia cells were incubated with different concentrations of 
fluvastatin, simvastatin, lovastatin or pravastatin for 48 hours. Growth inhibition 
was then determined using MTT reduction assay as described in Chapter 2. The 
IC50 value is the estimated concentration of the drug which causes 50% 
inhibition of the in vitro growth of that particular cell line under the prescribed 
experimental conditions. 
N.D.: Not determined. 
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3.2.2 Cytotoxicity of fluvastatin on murine myelomonocytic leukemia 
WEHI-3B JCS cells 
The cytotoxicity of fluvastatin on WEHI-3B JCS cells was examined by trypan 
blue exclusion assay. Dead cells would be stained blue by the dye while viable 
cells would remain colourless. After fluvastatin treatment for 24, 48 or 72 hours, 
WEHI-3B JCS cells were collected and enumerated by the cell viability analyzer. 
The viability of the cells remained over 80% even after treatment with 1.2 jjM 
fluvastatin for 72 hours (Figure 3.5), suggesting that fluvastatin was only slightly 
cytotoxic to WEHI-3B JCS cells. However, treatment of the WEHI-3B JCS cells 
with fluvastatin significantly reduced the leukemia cell number in a dose- and 
time-dependent manner (Figure 3.6). The results showed that fluvastatin only 
exerted minimal direct cytotoxicity on WEHI-3B JCS cells at the 
growth-inhibitory concentrations. 
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Figure 3.5. Effect of fluvastatin on the viability of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2 x l(f 
cells/mL) were incubated with solvent control (0.0024% dHiO) or different 
concentrations of fluvastatin for 24, 48 or 72 hours. Cell viability was then 
determined using the Vi-CELL XR cell viability analyzer. Data shown represent 
mean 士 SEM of three independent experiments. 0.05, < 0.01. 
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Figure 3.6. Effect of fluvastatin on the growth of the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2 x 10^  
cells/mL) were incubated with solvent control (0.0024% dHiO) or different 
concentrations of fluvastatin for 24, 48 or 72 hours. The cell number was then 
counted using the Vi-CELL XR cell viability analyzer. Data shown represent 
mean 士 SEM of three independent experiments. 0.05, ** < 0.01 • 
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3.2.3 Cytotoxicity of fluvastatin on primary murine myeloid cells 
Apart from the leukemia cells, the cytotoxicity of fluvastatin on normal cells was 
also examined. Primary murine peritoneal macrophages were used as an example 
to study the cytotoxic effect of fluvastatin on normal myeloid cells. Using the 
MTT reduction assay, it was found that fluvastatin treatment up to 1.2 juM for 24 
and 48 hours would not lead to any cytotoxic effects on the 
thioglycollate-elicited macrophages (Figure 3.7). Our results suggested that 
fluvastatin had little, if any, cytotoxic effect on normal myeloid cells at its 
growth-inhibitory concentrations for the myeloid leukemia cells. 
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Figure 3.7. Effect of fluvastatin on the viability of the murine peritoneal 
macrophages. Thioglycollate-elicited murine peritoneal exudate cells (1 x 10^  
cells/mL) were first cultured in 96-well plates and incubated at 37X for 3 hours 
to allow the peritoneal macrophages to adhere to the wells. After removing the 
non-adherent cells, the peritoneal macrophages were incubated with solvent 
control (0.0024% dHiO) or different concentrations of fluvastatin for 24 or 48 
hours. Cell viability was then determined using the MTT reduction assay as 
described in Chapter 2. Results were expressed as % inhibition of cell viability 
using solvent-treated cells as a control. Data shown represent mean 士 SEM of 
three independent experiments. 
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3.2.4 Kinetic and reversibility studies on the anti-proliferative effect of 
fluvastatin on WEHI-3B JCS cells 
Kinetic study on the anti-proliferative effect of fluvastatin on WEHI-3B JCS 
cells was performed by treating the cells with different concentrations of 
fluvastatin for 24, 48 or 72 hours. Cell proliferation was then measured by the 
MTT reduction assay (Figure 3.8) and H-TdR incorporation assay (Figure 3.9). 
It was shown that greater inhibitory effect on WEHI-3B JCS cell proliferation 
would be resulted from treatment with higher concentrations of fluvastatin. The 
inhibition was also increased with time. The results indicated that fluvastatin 
exerted anti-proliferative effect on the myeloid leukemia WEHI-3B JCS cells in a 
dose- and time-dependent manner. 
In order to investigate whether the anti-proliferative effect of fluvastatin was 
reversible, WEHI-3B JCS cells were treated with various concentrations of 
fluvastatin for different time periods, washed and re-incubated with complete 
medium for up to 48 hours. As shown in Figure 3.10, fluvastatin treatment for 12 
hours resulted in less than 20% inhibition on cell proliferation for all fluvastatin 
concentrations, while the inhibitory effect was enhanced with longer duration of 
drug treatment. This implied that the anti-proliferative effect of fluvastatin on 
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WEHI-3B JCS cells was partially reversible and significant anti-proliferative 
effect was seen after exposure of the cells to fluvastatin for just 24 hours. 
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Figure 3.8. Kinetic study on the growth-inhibitory effect of fluvastatin on 
the murine myelomonocytic leukemia WEHI-3B JCS cells as determined by 
MTT reduction assay. WEHI-3B JCS cells (2 x 10^  cells/mL) were incubated 
with solvent control (0.0024% dH�。）or different concentrations of fluvastatin 
for 24, 48 or 72 hours. Growth inhibition was then determined using MTT 
reduction assay as described in Chapter 2. Results were expressed as % 
inhibition of cell growth using solvent-treated cells as a control. Data shown 
represent mean 士 SEM of three independent experiments. 
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Figure 3.9. Kinetic study on the anti-proliferative effect of fluvastatin on 
the murine myelomonocytic leukemia WEHI-3B JCS cells as determined by 
^H-TdR incorporation assay. WEHI-3B JCS cells (2 x 10^  cells/mL) were 
incubated with solvent control (0.0024% dEbO) or different concentrations of 
fluvastatin for 24, 48 or 72 hours. Inhibition of cell proliferation was then 
determined using ^H-TdR incorporation assay as described in Chapter 2. Results 
were expressed as % inhibition of H-TdR incorporation using solvent-treated 
cells as a control. Data shown represent mean 士 SEM of three independent 
experiments. 
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Figure 3.10. Reversibility study on the anti-proliferative effect of 
fluvastatin on the murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2 x lo* cells/mL) were incubated with solvent control 
(0.0024% dHiO) or different concentrations of fluvastatin for 12, 24, 36 or 48 
hours. The cells were washed and replenished with complete medium at 
corresponding time point and all cultures were incubated for up to 48 hours. 
Inhibition of cell proliferation was then determined using the ^H-TdR 
incorporation assay as described in Chapter 2. Results were expressed as % 
inhibition of ^H-TdR incorporation using solvent-treated cells as a control. Data 
shown represent mean 土 SEM of three independent experiments. 
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3.2.5 Relationship between the anti-proliferative effect of fluvastatin and 
the cholesterol biosynthesis pathway in WEHI-3B JCS cells 
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol 
biosynthesis, and reduce the downstream products in the pathway. Hence, the 
relationship between the anti-proliferative effect of fluvastatin and the 
metabolites in the cholesterol biosynthesis pathway was investigated. It was 
shown that famesyl pyrophosphate (FPP) significantly reversed the inhibitory 
effect of fluvastatin on WEHI-3B JCS cells in a dose-dependent manner (Figure 
3.11). The inhibition on cell proliferation was also partially reversed by addition 
of geranylgeranyl pyrophosphate (GGPP), though the effect was found to be 
statistically insignificant (Figure 3.12). However, the addition of squalene 
exhibited no effect on the fluvastatin-treated cells (Figure 3.13), implying that 
restoration of cholesterol would not reduce the anti-proliferative effect of 
fluvastatin. This indicated that the anti-proliferative effect of fluvastatin was 
associated with the decreased concentrations of the isoprenoid intermediates FPP 
and GGPP in WEHI-3B JCS cells. 
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Figure 3.11. Anti-proliferative effect of fluvastatin in combinations with 
FPP on the murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B 
JCS cells (2 X io4 celis/mL) were incubated with solvent control (0.0024% 
dHiO), 1 }iM fluvastatin (FV) or different concentrations of FPP for 48 hours. 
Inhibition of cell proliferation was then determined using the H-TdR 
incorporation assay as described in Chapter 2. Results were expressed as % cell 
proliferation relative to the solvent-treated cells which were set as 100% cell 
proliferation. The bars represent mean 士 SEM of three independent experiments. 
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Figure 3.12. Anti-proliferative effect of fluvastatin in combinations with 
GGPP on the murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2 x lO^ cells/mL) were incubated with solvent control 
(0.0024% dH20), 1 |iM fluvastatin (FV) or different concentrations of GGPP for 
• 3 
48 hours. Inhibition of cell proliferation was then determined using the H-TdR 
incorporation assay as described in Chapter 2. Results were expressed as % cell 
proliferation relative to the solvent-treated cells which were set as 100% cell 
proliferation. The bars represent mean 士 SEM of three independent experiments. 
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Figure 3.13. Anti-proliferative effects of fluvastatin in combinations with 
SQ on the murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B 
JCS ceils (2 X 104 cells/mL) were incubated with solvent control (0.0024% 
dHiO), 1 jiM fluvastatin (FV) or different concentrations of squalene (SQ) for 48 
hours. Inhibition of cell proliferation was then determined using the H-TdR 
incorporation assay as described in Chapter 2. Results were expressed as % cell 
proliferation relative to the solvent-treated cells which were set as 100% cell 
proliferation. The bars represent mean 士 SEM of three independent experiments. 
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3.2.6 Effect of fluvastatin on the in vivo tumorigenicity of WEHI-3B JCS 
cells 
In addition to the in vitro experiments, the effect of fluvastatin on the in vivo 
tumorigenicity of WEHI-3B JCS cells was also examined. Briefly, WEHI-3B 
JCS cells were treated with different concentrations of fluvastatin for 20 hours, 
washed and injected intraperitoneally into the peritoneal cavity of BALB/c mice. 
After 10 days, WEHI-3B JCS cells were collected from the peritoneal cavity of 
the mice and the number of viable leukemia cells was then counted. The results 
suggested that in vitro pretreatment with fluvastatin significantly reduced the in 
vivo tumorigenicity of WEHI-3B JCS cells in syngeneic BALB/c mice, with 53% 
suppression of leukemic cell growth when the cells were pretreated in vitro with 
3 jiM fluvastatin (Figure 3.14). 
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Figure 3.14. Effect of in vitro pretreatment of WEHI-3B JCS cells with 
fluvastatin on the in vivo tumorigenicity of the leukemia cells in syngeneic 
BALB/c mice. WEHI-3B JCS cells (2 x lo^ cells/mL) were incubated with 
solvent control (0.0024% dHiO) or different concentrations of fluvastatin for 20 
hours and 1 x 10^  cells were injected intraperitoneally into each BALB/c mouse 
in groups of five. After 10 days, WEHI-3B JCS cells were collected from the 
peritoneal cavity of the mice and the number of viable leukemia cells was then 
counted using the Vi-CELL XR cell viability analyzer. The bars represent mean 士 
SEM of three independent experiments. p < 0.05. 
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3.2.7 Effect of fluvastatin on the cell cycle profile of WEHI-3B JCS cells 
One of the possible mechanisms for the observed anti-proliferative effect of 
fluvastatin is the disturbance of cell cycle. Hence, the possible involvement of 
this mechanism in growth inhibition was investigated. A cell cycle consists of 
several steps, including Go, Gi, S, G2 and M phases. DNA replication occurs at 
the S phase and the DNA content is doubled after S phase. Gi is a gap phase 
before S phase and prepares the cell for DNA synthesis, while G2 is another gap 
phase after S phase and prepares the cell for mitosis. Nuclear division occurs at 
M phase and followed by cell division. Instead of going to the S phase, some 
cells will enter the Go phase and become quiescent (Vermeulen et al., 2003). 
Propidium iodide (PI) is a dye which can intercalate into double-stranded DNA 
and gives out fluorescence signal. It helps to determine the amount of DNA 
content and thus the distribution of cells at different phases of the cell cycle. 
After fluvastatin treatment for 48 hours, the cell cycle profile of WEHI-3B JCS 
cells was studied by PI staining followed by flow cytometric analysis. 
Representative results of the cell cycle profile were shown in Figure 3.15A and 
the cell cycle distribution was summarized in Figure 3.15B. There was a 
significant increase in the proportion of cells at GQ/GI phase, accompanied by a 
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significant decrease in the proportion of cells at S phase at higher concentrations 
of fluvastatin. No obvious change in the G2/M phase was observed. This implied 
that fluvastatin would result in cell cycle arrest at GQ/GI phase. In addition, this 
phenomenon was found to be dose- and time-dependent as shown in Table 3.2. 
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Figure 3.15. Effect of fluvastatin on the cell cycle distribution of the 
murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells 
(2 X lO^ cells/mL) were synchronized by serum starvation for 24 hours and then 
incubated with solvent control (0.0024% dH:。）or different concentrations of 
fluvastatin for 48 hours. The cells were then fixed with ethanol, stained with PI 
and analyzed by flow cytometry. The cell cycle distribution patterns were 
calculated by the ModFit LT software. (A) Representative graphs showing the 
cell cycle profile of fluvastatin-treated cells. (B) Bar chart showing the cell cycle 
distribution of the cells with data shown represent mean ± SEM of three 
independent experiments. * 尸 < 0.05, ** ；？ < 0.01 • 
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Table 3.2. Kinetic study on the effect of fluvastatin on the cell cycle 
distribution of the murine myelomonocytic leukemia WEHI-3B JCS cells. 
Treatment of % of cells at 36 h % of cells at 48 h 
cells GQ/GI S G2/M Go/Gi S G2/M 
Solvent control 41.8 50.26 7.94 35.59 52.18 12.23 
0.8 i^M FV 53.47 34.68 11.85 46.74 42.73 11.13 
1 ^iMFV 59.61 30.52 9.87 53.36 36.76 9.88 
1.2|iMFV 60.57 25.38 14.05 60.15 31.41 8.44 
WEHI-3B JCS cells (2 x lO"^  cells/mL) were synchronized by serum starvation 
for 24 hours and then incubated with solvent control (0.0024% dHiO) or 
different concentrations of fluvastatin for 36 or 48 hours. The cells were then 
fixed with ethanol, stained with PI and analyzed by flow cytometry. The cell 
cycle distribution patterns were calculated by the ModFit LT software. The data 
shown are representative of three independent experiments with similar results. 
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3.2.8 Effect of fluvastatin on the expression of cell cycle regulatory proteins 
in WEHI-3B JCS cells 
Cell cycle progression is strictly controlled by different cellular proteins. The 
major regulatory proteins are the cyclin-dependent kinases (cdks). They are a 
group of serine/threonine protein kinases that are activated at particular points 
during the cell cycle, phosphorylating target proteins to induce downstream 
processes. Cdk activation is regulated by cyclins, which have differential 
expression at different phases of the cell cycle (Branzei et al., 2008). 
As fluvastatin was shown to halt the cell cycle progression of WEHI-3B JCS 
cells at Go/Gi phase as described in Section 3.2.7, the protein expression of 
cyclins and cdks responsible for the transition from the Gq/Gi phase to S phase 
was investigated by Western blotting. It was found that fluvastatin 
down-regulated the protein expression of cyclin E, cdk2 and cdk6 in a 
dose-dependent manner (Figure 3.16). 
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Figure 3.16. Effect of fluvastatin on the expression of cell cycle regulatory 
proteins in the murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2 x lO* cells/mL) were synchronized by serum starvation 
for 24 hours and then incubated with solvent control (0.0024% dH20) or 
different concentrations of fluvastatin for 48 hours. Proteins were extracted and 
analyzed by Western blotting as described in Chapter 2. The housekeeping 
protein p-actin was used as an internal standard for comparison. (A) 
Representative Western blots showing the expression of cell cycle regulatory 
proteins in fluvastatin-treated cells. (B) Bar chart showing the protein band 
intensities of the fluvastatin-treated cells relative to those of the solvent-treated 
cells as quantified by the ImageJ software. The bars represent mean ± SEM of 
three independent experiments. * p < 0.05, < 0.01, 0.001. 
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3.3 Discussion 
Previous reports have suggested the suppressive effects of statins on various 
types of tumors (Sassano et al., 2008). In the present study, fluvastatin, 
simvastatin and lovastatin were shown to inhibit the growth of the murine 
myelomonocytic leukemia WEHI-3B JCS cells，the human promyelocytic 
leukemia HL-60 cells and the murine macrophage-like tumor PUS-1.8 cells in a 
dose-dependent manner. According to the Developmental Therapeutics Program 
NCI/NIH, the average 50% lethal concentration (LC50) of simvastatin and 
lovastatin are 24.7 |iM and 29.3 \xM respectively in the tumor cell line screening 
conducted in 2009 (Developmental Therapeutics Program NCI/NIH, 2009). Our 
present study showed that statins had much lower IC50 values for the myeloid 
tumors, implying the relative high potency of statins on myeloid leukemia cells. 
Fluvastatin, simvastatin and lovastatin were found to exhibit growth-inhibitory 
effect on myeloid leukemia cells to different extent. It should be noted that only 
pravastatin did not exhibit any inhibitory effect on leukemia cell growth among 
the four statins examined, even at a concentration up to 50 In fact, 
pravastatin was demonstrated to have no growth-inhibitory effect on breast 
cancer at doses as high as 200 jxM and suggested to have no anti-tumor effect 
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both in vitro and in vivo (Campbell et al., 2006; Gbelcova et al., 2008). The 
difference in the anti-leukemic effects of statins may be resulted from their 
variations in chemical structure, pharmacokinetics and pharmacodynamics 
(Schachter, 2005). Fluvastatin, simvastatin and lovastatin are relatively lipophilic, 
while pravastatin is more hydrophilic. Hydrophilic statins are relatively 
hepatoselective in distribution, as they cannot cross the lipid bilayer of the cell 
membrane and primarily depend on the organic anion transporters on hepatic cell 
membrane for cell entry. On the contrary, lipophilic statins can penetrate the cell 
membrane directly and lead to pleiotropic effects in extrahepatic cells (Ichihara 
et al., 2002). Therefore, the lipophilic nature of fluvastatin, simvastatin and 
lovastatin may be responsible for their observed anti-proliferative effect on 
myeloid leukemia cells. Interestingly, fluvastatin has the least ability to reduce 
low-density lipoprotein cholesterol among currently available statins (Schachter, 
2005), but was shown to have the most potent anti-proliferative effect on 
myeloid leukemia cells in the present study. The murine myelomonocytic 
leukemia WEHI-3B JCS cells were found to be the most sensitive cell line in 
response to the statins being tested. As a result, fluvastatin and WEHI-3B JCS 
cells were chosen as the representative drug and cell model respectively for 
further mechanistic studies in our project. 
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Next, the cytotoxicity of fluvastatin was examined. It was shown that fluvastatin 
was only slightly cytotoxic to WEHI-3B JCS cells at its growth-inhibitory 
concentrations, indicating that the observed anti-proliferative effect could not be 
attributed solely to the direct cytotoxicity of the drug on the leukemia cells. 
Furthermore, fluvastatin did not result in any cytotoxic effects on the 
thioglycollate-elicited murine peritoneal macrophages, implying that fluvastatin 
exerted little, if any, adverse effects on normal myeloid cells. Our results 
demonstrated that fluvastatin is relatively safe and tumor-specific. In fact, statins 
are generally well tolerated and serious side effects are rare (Black, 2002). Being 
a currently approved drug, the safety of fluvastatin has been assured. 
The anti-proliferative effect of fluvastatin on WEHI-3B JCS cells was shown to 
be both dose- and time-dependent. A higher drug concentration or a longer 
incubation time for treatment would result in a greater inhibition of leukemic cell 
growth. Moreover, it was found that the anti-proliferative effect of fluvastatin 
was partially reversible during the early period of exposure. Indeed, it was shown 
that apoptotic cancer cells were able to survive after removal of apoptotic 
inducers if they had not reached the stage of apoptotic nuclear fragmentation. 
This reversibility of apoptosis was observed in various types of tumors (Tang et 
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al, 2009). Hence, fluvastatin treatment for at least 24 hours was needed in order 
to attain sufficient inhibition of WEHI-3B JCS cell proliferation. 
Rapidly proliferating cells such as cancer cells require a high rate of membrane 
lipid biosynthesis. Thus, the direct inhibitory effect of fluvastatin on cholesterol 
biosynthesis may be a possible reason for the observed growth suppression on 
WEHI-3B JCS cells. However, addition of FPP and GGPP, but not squalene, was 
found to restore the proliferation of WEHI-3B JCS cells, with a significant effect 
observed for FPP. Squalene is a relatively downstream product in cholesterol 
biosynthesis pathway. Its failure in reversing the fluvastatin-mediated growth 
inhibition suggested that the anti-proliferative effect of fluvastatin on WEHI-3B 
JCS cells was probably not related to the direct cholesterol-lowering property of 
fluvastatin, which is consistent with the incapability of squalene and cholesterol 
to reduce lovastatin-induced apoptosis in promyelocytic leukemia NB4 cells (Xia 
et al., 2001). FPP and GGPP are isoprenoid intermediates produced upstream of 
squalene in the cholesterol biosynthetic pathway. They are responsible for 
providing lipid attachment sites for of a variety of proteins, including the small 
guanosine triphosphate (GTP)-binding protein Ras and Ras-like proteins such as 
Rho and Rac, and are important for their membrane attachment and biological 
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function (Collisson et al., 2003). Ras and Rho are translocated to the membrane 
after isoprenylation with FPP and GGPP respectively. Ras is involved in cell 
growth and proliferation (Cafforio et al., 2005), while Rho is associated with cell 
adhesion and invasion (Kusama et aL, 2002). Inhibition of HMG-CoA reductase 
by fluvastatin would thus deplete FPP and GGPP, inhibiting the isoprenylation of 
proteins involved in cell proliferation and survival, leading to the observed 
growth suppression on WEHI-3B JCS cells. Indeed, the famesyltransferase 
inhibitor R11597 was shown to exhibit anti-leukemic activity in leukemia 
patients, suggesting the importance of famesylation in the progression of 
leukemia (Appelbaum, 2003). 
Besides the in vitro studies, we also examined the effect of fluvastatin on the in 
vivo tumorigenicity of the myeloid leukemia WEHI-3B JCS cells. It was 
demonstrated that in vitro pretreatment of WEHI-3B JCS cells with fluvastatin 
significantly reduced the in vivo tumorigenicity of leukemia cells in syngeneic 
BALB/c mice. Previous reports have also shown that fluvastatin exhibited 
significant in vivo anti-tumor effect on implanted hepatocarcinoma in rats 
(Paragh et al., 2003), pancreatic cancer MIAPaCa-2 xenografts in mice (Bocci et 
al., 2005) as well as in patients with high grade breast cancer (Garwood et al., 
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2010). Further investigation on the in vivo anti-leukemic activity of fluvastatin 
should be carried out by oral or parenteral administration of the drug into 
tumor-bearing mice. 
There are increasing evidence suggesting that cancer cells, especially those of 
hematopoietic origin, are incapable of surviving from simultaneous disruption of 
the cell cycle and survival signaling pathways (Dai et al., 2007). Moreover, 
different inhibitors of cholesterol biosynthesis, acting on distinct enzymes, have 
varying effects on cell cycle progression (Sanchez-Martin et al‘, 2007). Hence, 
we investigated the effect of fluvastatin on the cell cycle progression in 
WEHI-3B JCS cells. It was shown that fluvastatin treatment of WEHI-3B JCS 
cells resulted in cell cycle arrest at Gq/Gi phase in a dose- and time-dependent 
manner. Our results are in line with others who demonstrated that fluvastatin 
induced Gq/Gi arrest in renal cancer (Horiguchi et al., 2004) and multiple 
myeloma (Baulch-Brown et al., 2007). In the cell cycle machinery, the Gi/S 
transition is promoted through the inactivation of the retinoblastoma protein 
(Rb)-E2F-1 complex by cyclin D/cdk4 or 6 during early Gi, or by cyclin E/cdk2 
during late Gi. Cyclin/cdk complex phosphorylates Rb, leading to the 
dissociation of Rb and the transcription factor E2F-1, which in turn activates the 
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transcription of genes coding for proteins required for S phase progression 
(Vermeulen et al., 2003; Steinman, 2002). In the present study, the protein 
expression of cell cycle regulatory proteins responsible for Gi/S transition was 
investigated by Western blotting. Fluvastatin was found to down-regulate the 
protein expression of cyclin E, cdk2 and cdk6. This might affect the formation of 
cyclin D/cdk6 and cyclin E/cdk2 complexes, restricting the progression of the 
cells to S phase, leading to the observed cell cycle arrest at the Gq/Gi phase. 
Collectively, our results showed that fluvastatin exhibited potent 
anti-proliferative effect on murine myelomonocytic leukemia WEHI-3B JCS 
cells both in vitro and in vivo. This anti-leukemic activity might be resulted from 
disruption of isoprenylation of proteins important for cell growth and 
proliferation. In addition, the anti-proliferative effect of fluvastatin might be due 
to cell cycle arrest at Gq/Gi phase through the down-regulation of cyclin E, cdk2 
and cdk6 protein expression. Other possible mechanisms that might be involved 
in the observed growth-inhibitory effect of fluvastatin on the leukemia WEHI-3B 
JCS cells would be discussed in the next chapter. 




Effects of Fluvastatin on 
Murine Myelomonocytic 
Leukemia WEHI-3B JCS 
Cells 
Chapter 4 Apoptosis- and Differential ion-inducing Effects 
4.1 Introduction 
Programmed cell death is important for normal embryogenesis, tissue 
homeostasis and removal of damaged or transformed cells (Wu et al., 2010). 
There are three distinct types of physiological cell death which are defined 
according to their morphological criteria: apoptosis, autophagy and necrosis. 
Apoptosis is characterized by cell shrinkage, membrane blebbing, nuclear 
condensation and fragmentation and the formation of apoptotic bodies (Krysko et 
al., 2008). Autophagy is characterized by the vacuolization of cytoplasm and 
organelles, leading to the accumulation of double-membraned autophagic 
vacuoles which are finally delivered to lysosomes for degradation (Geng et al., 
2010). Necrosis is characterized by cytoplasmic swelling of the organelles, 
rupture of plasma membrane and lysis of cells (Kroemer et al.’ 2009). A 
significant difference between necrotic and apoptotic cell death is that necrosis 
involves the rupture of plasma membrane and release of cellular contents which 
may trigger inflammatory responses, while the cellular contents in apoptotic 
bodies are engulfed by phagocytes (Nagata et al., 2003). 
The intrinsic (mitochondrial) and extrinsic (death receptor) pathways are two 
major pathways identified for apoptosis. In the intrinsic pathway, 
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mitochondria-mediated processes result in the release of cytochrome c from the 
mitochondrial intermembrane space, followed by the formation of apoptosome 
and activation of caspase-9 as well as the downstream caspases. These signaling 
pathways are modulated by the Bcl-2 family proteins. The pro-apoptotic Bcl-2 
family proteins (e.g. Bid, Bax and Bad) permeabilize the outer mitochondrial 
membrane to facilitate cytochrome c release, while anti-apoptotic Bcl-2 family 
members (Bcl-2 and Bcl-xL) counteract this event (Chen et al., 2010). In the 
extrinsic pathway, the binding of death ligands, such as TNF or Fas ligand 
(FasL), to their corresponding receptors stimulates the activation of caspase-8 
(Vaculova et al, 2010). The two pathways eventually activate the effector 
caspases, such as caspase-3, and in turn trigger the activation of nucleases such 
as caspase-activated DNase (CAD), leading to nuclear fragmentation (Kajstura et 
al., 2007). The induction of apoptosis has been extensively studied for the 
treatment of cancer, including leukemia (El-Khoury et al., 2010; Cakir et al., 
2010). 
Apart from apoptosis, induction of terminal differentiation is an alternative 
approach for anti-leukemic therapies. Leukemia is a heterogeneous group of 
diseases with different genetic abnormalities. In particular, impaired 
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differentiation and enhanced proliferation and survival are the two characteristics 
of leukemia cells (Petrie et al., 2009). Indeed, a variety of chemicals such as 
all-trans retinoic acid, vitamin D and hematopoietic cytokines have been shown 
to effectively induce the differentiation of leukemia cells (Nowak et al., 2009). A 
recent report has shown that statins can exert various effects on immune 
responses (Tristano et al., 2006). Thus, it is of interest to examine the underlying 
mechanisms of statin-induced immunomodulation and its possible beneficial 
effects on cancer treatment. 
In this chapter, parameters such as chromatin condensation and DNA 
fragmentation were used to investigate whether fluvastatin could exert 
apoptosis-inducing effect on the murine myelomonocytic leukemia WEHI-3B 
JCS cells. The possible involvements of mitochondrial membrane potential, 
caspase activities and the expression of the apoptosis-inducing factor (AIF) were 
studied for fluvastatin-mediated apoptosis. In addition, the morphology, cell size 
and granularity of the cells after fluvastatin treatment were examined for the 
differentiation-stimulating effect of fluvastatin. As a preliminary study, the 
production of nitric oxide (NO) from the fluvastatin-treated murine peritoneal 
macrophages was also measured so as to look into the possible 
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immunomodulatory effect of fluvastatin on macrophages. 
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4.2 Results 
4.2.1 Induction of chromatin condensation in WEHI-3B JCS cells by 
fluvastatin 
Chromatin condensation is one of the classical hallmarks of apoptosis (Lu et al, 
2005). To visualize the nucleus, fluvastatin-treated cells were stained with the 
blue-fluorescent dye Hoechst 33342. It was observed that fluvastatin treatment 
resulted in chromatin condensation in the nuclei of WEHI-3B JCS cells, while no 
obvious chromatin condensation was seen in the nuclei of the control cells 
(Figure 4.1). Our results suggested that fluvastatin could induce apoptosis in 
WEHI-3B JCS cells. 
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Figure 4.1. Induction of chromatin condensation in the fluvastatin-treated 
murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells 
(2 X io4 cells/mL) were incubated with solvent control (0.0024% dHiO) or 
different concentrations of fluvastatin for 48 hours. The cells were 
cytocentrifuged on microscopic glass slides, fixed with paraformaldehyde and 
stained with Hoechst 33342. The scale bar represents 50 jim. Magnification is 
200X. 
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4.2.2 Induction of DNA fragmentation in WEHI-3B JCS cells by 
fluvastatin 
Degradation of chromosomal DNA into fragments in multiples of 180 - 200 bp 
by endogenous DNases is another crucial hallmark of apoptosis (Saraste et al.’ 
2000). To examine this biochemical event, DNA was extracted from 
fluvastatin-treated WEHI-3B JCS cells and subjected to agarose gel 
electrophoresis. DNA ladders were observed after fluvastatin treatment in a dose-
(Figure 4.2) and time-dependent maimer (Figure 4.3). The presence of DNA 
ladders implied that DNA fragmentation and thus apoptosis did occur in 
fluvastatin-treated cells. 
The amount of fragmented DNA present in WEHI-3B JCS cells can be quantified 
by the Cell Death ELISA as described in Chapter 2. It was shown that an 
increasing amount of mono- and oligonucleosomes were present in the cell 
lysates after fluvastatin treatment in a dose-dependent manner (Figure 4.4). This 
further confirmed the apoptosis-inducing effect of fluvastatin. 
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^ ^ H ^ ^ ^ ^ l f c l � Lane 1: 100 bp DNA marker 
• Lane 2: Solvent control 
Lane 3: 0.6 [iM fluvastatin 
Lane 4: 0.8 jiM fluvastatin 
Lane 1 [iM fluvastatin 
Lane 1.2 \iM fluvastatin 
Figure 4.2. Induction of DNA fragmentation in the fluvastatin-treated 
murine myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells 
(2 X LO4 cells/mL) were incubated with solvent control (0.0024% dHiO) or 
different concentrations of fluvastatin for 48 hours. Cellular DNA was extracted 
with IGEPAL CA-630 lysis buffer and analyzed by electrophoresis on 2% 
agarose gel stained with ethidium bromide. 
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Figure 4.3. Kinetic study on the induction of DNA fragmentation in the 
fluvastatin-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2 x lO^ cells/mL) were incubated with solvent control 
(0.0024% dHiO) or 1 jxM fluvastatin for 24 or 48 hours. Cellular DNA was 
extracted with IGEPAL CA-630 lysis buffer and analyzed by electrophoresis on 
2% agarose gel stained with ethidium bromide. 
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Figure 4.4. Nucleosome enrichment in the fluvastatin-treated murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2 x 10^  
cells/mL) were incubated with solvent control (0.0024% dHiO) or different 
concentrations of fluvastatin for 24 hours. Cytosolic nucleosomes were isolated 
and subjected to cell death ELISA as described in Chapter 2. Results were 
expressed as enrichment factor of nucleosomes using solvent-treated cells as a 
control. The bars represent mean 士 SEM of three independent experiments. 
0.001. 
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4.2.3 Effect of fluvastatin on the mitochondrial membrane potential in 
WEHI-3B JCS cells 
The mitochondria are believed to play a major role in the apoptotic process. For 
instance, the release of apoptogenic factors from the intermembrane space into 
the cytosol is regulated by the mitochondrial membrane potential and 
mitochondrial membrane permeability (Ly et al., 2003). The possible 
involvement of mitochondrial membrane potential in the apoptosis-inducing 
effect of fluvastatin was investigated using the fluorescent dye JC-1. JC-1 exists 
as red-fluorescent J-aggregates in normal cells but dissipates into 
green-fluorescent monomers upon a loss in the mitochondrial membrane 
potential (Mathur et al., 2000). Hence, a shift from red to green fluorescence 
would indicate mitochondrial membrane depolarization. 
By flow cytometry, it was observed that there was an increase in the percentage 
of WEHI-3B JCS cells with higher green to red fluorescence ratio after 
fluvastatin treatment, from 1.7% in the control to 64.56% in cells treated with 1.2 
^M fluvastatin for 48 hours (Figure 4.5). The effect of fluvastatin was found to 
be dose- and time-dependent as shown in Table 4.1. This suggested that 
fluvastatin would lead to mitochondrial membrane depolarization in WEHI-3B 
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JCS cells. 
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Figure 4.5. Flow cytometric analysis on the mitochondrial membrane 
potential of the fluvastatin-treated murine myelomonocytic leukemia 
WEHI-3B JCS cells. WEHI-3B JCS cells (2 x icf cells/mL) were incubated 
with solvent control (0.0024% dHiO) or different concentrations of fluvastatin 
for 48 hours. The cells were stained with the dye JC-1 and analyzed by flow 
cytometry. The percentage of cells in the lower right region (Rl), having a higher 
green to red fluorescence ratio, was calculated by the WinMDI software. 
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Table 4.1. Kinetic study on the effect of fluvastatin on the mitochondrial 
membrane potential of the murine myelomonocytic leukemia WEHI-3B JCS 
cells. 
Fluvastatin % of green fluorescent cells 
concentration 24 h 36 h 48 h 
Solvent control 2.15 1.33 1.70 
0.6 |iM 3.71 2.98 4.63 
0.8 |liM 5.24 8.18 15.26 
1 jiM 11.02 14.51 40.37 
1.2 ^ 29.44 64.56 
WEHI-3B JCS cells (2 x lO'^  cells/mL) were incubated with solvent control 
(0.0024% dHiO) or different concentrations of fluvastatin for 24, 36 or 48 hours. 
The cells were stained with the dye JC-1 and analyzed by flow cytometry. The 
percentage of green fluorescent cells was calculated by the WinMDI software. 
The data shown are representative of three independent experiments with similar 
results. 
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4.2.4 Effect of fluvastatin on the caspase activities in WEHI-3B JCS cells 
Apoptosis is regulated by a family of cysteine aspartic acid-specific proteases 
called caspases. They are normally present as inactive zymogens with little or no 
protease activity. They are highly specific for protein substrates containing Asp 
and utilizing their Cys side chain for catalyzing peptide bond cleavage (Taylor et 
al., 2008). Caspases involved in the apoptotic pathway are divided into initiator 
caspases (caspase-8, -9, and -10), which are activated to trigger the proteolytic 
processing of other caspases, and effector caspases (caspase-3, -6, and -7), which 
are responsible for cleaving most of the substrates in apoptosis (Pop et al., 2009). 
The initiators caspase-8 from the extrinsic death receptor pathway and caspase-9 
from the intrinsic mitochondrial pathway converge at the activation of main 
apoptotic executioner caspase-3, leading to the cleavage of downstream cellular 
proteins and eventually resulting in cell destruction (Lowe et al., 2004; 
Krautwald et a/., 2010). 
Since fluvastatin was shown to induce chromatin condensation and DNA 
fragmentation in the previous sections, the activities of caspase-3, -8 and -9 were 
studied by a fluorometric assay as described in Chapter 2 to determine whether 
the intrinsic and/ or extrinsic pathways were involved in the fluvastatin-induced 
1 3 8 
Chapter 4 Apoptosis- and Differential ion-inducing Effects 
apoptosis. It was found that fluvatatin treatment enhanced the activities of 
caspase-3, -8 and -9 in WEHI-3B JCS cells in a dose-dependent manner (Figure 
4.6 to 4.8). There were 7.23-, 26.58- and 26.66-fold increase in the activities of 
caspase-3, -8 and -9 respectively after treatment with 1.2 [iM fluvastatin. In 
addition, the suppression of all three caspase activities by the corresponding 
caspase inhibitors demonstrated the specificity of the assay. Therefore, our 
present study showed that caspase-3, -8 and -9 were involved in 
fluvastatin-induced apoptosis. As caspase-8 and -9 are responsible for the 
extrinsic and intrinsic apoptotic pathways respectively, the results implied that 
fluvastatin triggered apoptosis via both the extrinsic and intrinsic pathways. 
Moreover, the role of caspases in fluvastatin-induced apoptosis was further 
examined using the cell permeable and irreversible pan-caspase inhibitor 
Z-VAD-FMK. The pan-caspase inhibitor only slightly diminished the amount of 
oligonucleosomes present in the cell lysates after fluvastatin treatment (Figure 
4.9). This suggested that fluvastatin-induced apoptosis was not solely dependent 
on caspases. 
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Figure 4.6. Effect of fluvastatin on the caspase-3 activity in the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2 x 10^  
cells/mL) were incubated with solvent control (0.0024% (fflbO) or different 
concentrations of fluvastatin for 48 hours. Proteins were extracted and added to 
the fluorogenic substrate in the presence or absence of caspase-3 inhibitor 
(Ac-DEVD-CHO). Fluorescence reading was then measured and the caspase-3 
activity was expressed as AMC release in relative fluorescence units (RFU) as 
described in Chapter 2. The data shown represent mean 士 SEM of three 
independent experiments. 0.00L 
1 4 0 
Chapter 4 Apoptosis- and Differential ion-inducing Effects 
0.8-1 
*** • + inhibitor 
S 0.6- • - inhibitor 
LL _ 
Q： _ 
* * * 
% ^ i 
I �.4- 圓 % 
s - I i 
** I 爹 爹 
� J m 产 r - 1 , 1 r n , l n , i -
Z � 
Fluvastatin concentration (i^ iM) 
Figure 4.7. Effect of fluvastatin on the caspase-8 activity in the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2 x 10^  
cells/mL) were incubated with solvent control (0.0024% dH20) or different 
concentrations of fluvastatin for 48 hours. Proteins were extracted and added to 
the fluorogenic substrate in the presence or absence of caspase-8 inhibitor 
(Ac-IETD-CHO). Fluorescence reading was then measured and the caspase-8 
activity was expressed as AMC release in RFU as described in Chapter 2. The 
data shown represent mean 士 SEM of three independent experiments. 
0.001. 
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Figure 4.8. Effect of fluvastatin on the caspase-9 activity in the murine 
myelomonocytic leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2 x 10^  
cells/mL) were incubated with solvent control (0.0024% dHaO) or different 
concentrations of fluvastatin for 48 hours. Proteins were extracted and added to 
the fluorogenic substrate in the presence or absence of caspase-9 inhibitor 
(Ac-LEHD-CHO). Fluorescence reading was then measured and the caspase-9 
activity was expressed as AMC release in RPU as described in Chapter 2. The 
data shown represent mean 士 SEM of three independent experiments. 
***;?< 0.001. 
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Figure 4.9. Effect of pan-caspase inhibitor on nucleosome enrichment in 
the fluvastatin-treated murine myelomonocytic leukemia WEHI-3B JCS 
cells. WEHI-3B JCS cells (2 x cells/mL) were incubated with solvent control 
(0.0024% dHiO), 1 [iM fluvastatin or different concentrations of Z-VAD-FMK 
for 24 hours. Cytosolic nucleosomes were isolated and subjected to cell death 
ELISA as described in Chapter 2. Results were expressed as enrichment factor of 
nucleosomes using solvent-treated cells as a control. 
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4.2.5 Effect of fluvastatin on the expression of pro-apoptotic protein AIF in 
WEHI-3B JCS cells 
A variety of death signals act on the mitochondria to result in the release of 
pro-apoptotic proteins normally situated at the mitochondrial intermembrane 
space, irrespective of different proposed mechanisms of membrane 
permeabilization (Ly et al, 2003; van Gurp et al., 2003). These mitochondrial 
proteins trigger downstream apoptotic processes via caspase-dependent or 
-independent pathways. For instance, cytochrome c binds to apoptotic protease 
activating factor-1 (Apaf-1) and induces caspase-9 activation in the apoptosome. 
Smac/DIABLO and HtrA2/0mi bind to inhibitors of apoptosis proteins (lAPs) to 
remove their inhibition on activated caspases. On the other hand, 
apoptosis-inducing factor (AIF) and endonuclease G are translocated to the 
nucleus and are responsible for the caspase-independent DNA degradation 
(Kandasamy et al., 2003; Antonsson, 2004). 
In our present study, it was shown that fluvastatin up-regulated the protein 
expression of cytosolic AIF with a down-regulation of mitochondrial AIF protein 
expression in WEHI-3B JCS cells (Figure 4.10). This suggested the translocation 
of AIF from the mitochondria to the cytosol upon fluvastatin treatment in a 
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Figure 4.10. Effect of fluvastatin on the protein expression of cytosolic and 
mitochondrial AIF in the murine myelomonocytic leukemia WEHI-3B JCS 
cells. WEHI-3B JCS cells (2 x cells/mL) were incubated with solvent control 
(0.0024% dHiO) or different concentrations of fluvastatin for 48 hours. Cytosolic 
and mitochondrial proteins were extracted and analyzed by Western blotting as 
described in Chapter 2. The housekeeping protein p-actin was used as an internal 
standard for comparison. (A) Representative Western blots showing the protein 
expression of cytosolic and mitochondrial AIF in fluvastatin-treated cells. (B) 
Bar chart showing the protein band intensities quantified by the ImageJ software. 
The data shown represent mean 士 SEM of three independent experiments. 
**;7<0.01, 0.001. 
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4.2.6 Effect of fluvastatin on the morphology of WEHI-3B JCS cells 
Previous studies have reported that the myelomonocytic leukemia WEHI-3B JCS 
cells can be induced to undergo monocytic differentiation, characterized by the 
reduction in nucleus to cytoplasm ratio, protrusion of cytoplasmic borders and 
the presence of cytoplasmic vacuoles (Lui et al., 2005; Hu et al., 2010). 
Therefore, the differentiation-inducing potential of fluvastatin was examined in 
this study. By morphological staining, it was observed that fluvastatin-treated 
WEHI-3B JCS cells showed a decrease in nucleus to cytoplasm ratio when 
compared to the control (Figure 4.11). Vacuolation also appeared in the 
cytoplasm. This suggested that fluvastatin was able to induce monocytic 
differentiation of WEHI-3B JCS cells. 
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Figure 4.11. Morphology of fluvastatin-treated murine myelomonocytic 
leukemia WEHI-3B JCS cells. WEHI-3B JCS cells (2 x lO^ cells/mL) were 
incubated with solvent control (0.0024% dHiO) or different concentrations of 
fluvastatin for 72 hours. The cells were cytocentrifuged on microscopic glass 
slides and stained with Hemacolor® solutions as described in Chapter 2. The 
scale bar represents 50 jim. Magnification is 400X. 
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4.2.7 Effect of fluvastatin on the cell size and granularity of WEHI-3B JCS 
cells 
Apart from the direct observation of cell morphology, the cell size and 
granularity of fluvastatin-treated WEHI-3B JCS cells were studied by flow 
cytometry. Forward scatter (FSC) and side scatter (SSC) are two parameters of 
flow cytometry which indicate the size and granularity of cells respectively. It 
was shown that fluvastatin treatment increased the granularity of WEHI-3B JCS 
cells, though the cell size remained relatively the same (Figure 4.12). This 
confirmed the differentiation-inducing property of fluvastatin on WEHI-3B JCS 
cells. 
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Figure 4.12. Flow cytometric analysis on the cell size and granularity of the 
fluvastatin-treated murine myelomonocytic leukemia WEHI-3B JCS cells. 
WEHI-3B JCS cells (2 x lO^ cells/mL) were incubated with solvent control 
(0.0024% dHiO) or different concentrations of fluvastatin for 72 hours. The cells 
were then subjected to flow cytometric analysis. The change in cell size and 
granularity was calculated by the FACSDiva software. 
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4.2.8 Immunomodulation of murine peritoneal macrophages by fluvastatin 
Macrophages are crucial for inflammation and host defense. They can suppress 
the growth of tumor cells and microorganisms when activated (Kim et al, 2003). 
Nitric oxide (NO), an important regulator for tissue homeostasis, is one of the 
effector molecules generated by macrophages against tumors (Min et al., 2010). 
The effect of fluvastatin on the NO production by lipopolysaccharide 
(LPS)-activated murine peritoneal macrophages was thus examined. It was found 
that fluvastatin significantly elevated NO production in LPS-treated macrophages 
(Figure 4.13). This implied that fluvastatin augmented the stimulatory effect of 
LPS on macrophage activation. 
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Figure 4.13 Effect of fluvastatin on NO production from the LPS-treated 
murine peritoneal macrophages. Thioglycollate-elicited murine peritoneal 
exudate cells (1 x 10^ cells/mL) were first cultured in 96-well plates and 
incubated at 37�C for 3 hours to allow the peritoneal macrophages to adhere to 
the wells. After removing the non-adherent cells, the peritoneal macrophages 
were incubated with solvent control (0.0024% dHiO) or different concentrations 
of fluvastatin in the presence of LPS for 48 hours. NaNOi concentration was then 
determined using Griess reagent as described in Chapter 2. The data shown 
represent mean 士 SEM of three independent experiments. ** < 0.01, *** p < 
0.001. 
1 5 2 
Chapter 4 Apoptosis- and Differential ion-inducing Effects 
4.3 Discussion 
In Chapter 3, we have demonstrated that fluvastatin inhibited the proliferation of 
the murine myelomonocytic leukemia WEHI-3B JCS cells. It was shown that 
disturbance of protein isoprenylation and cell cycle arrest at GQ/GI phase might 
contribute to the observed growth suppression. However, other possible 
mechanisms can also be involved in the inhibition of leukemic cell proliferation. 
In this chapter, the apoptosis- and differentiation-inducing effects of fluvastatin 
on the leukemia WEffl-3B JCS cells were investigated. 
Statins have been reported to trigger apoptosis of tumor cells in a tumor-specific 
manner (Wong et al., 2002). In the present study, WEHI-3B JCS cells were 
shown to undergo chromatin condensation and nuclear fragmentation, the two 
significant biochemical hallmarks of apoptosis, upon fluvastatin treatment. Since 
we had demonstrated that the anti-proliferative effect of fluvastatin was unlikely 
to be associated with its direct cytotoxicity on the leukemia cells as shown in 
Chapter 3, the current data implied the occurrence of apoptosis rather than 
necrosis. In fact, it was suggested that apoptotic DNA fragmentation might not 
be a crucial event for cell death, but to prevent the accumulation of DNA, which 
would stimulate autoimmune responses if released into the cytosol (Taylor et al., 
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2008). 
Mitochondria play a key role in apoptosis. Hence, mitochondrial events were 
examined in fluvastatin-treated WEHI-3B JCS cells. It was found that fluvastatin 
induced mitochondrial membrane depolarization in WEHI-3B JCS cells, 
suggesting that the mitochondria are involved in fluvastatin-induced apoptosis. A 
decrease in mitochondrial membrane potential would favor the opening of the 
permeability transition pore (PIT) and in turn associated with the release of 
mitochondrial intermembrane proteins involved in apoptosis (Han et al., 2010). 
The activities of the major apoptotic regulators, caspases, were investigated. It 
was demonstrated that fluvastatin treatment resulted in an elevation in the 
activities of caspase-3, -8 and -9 in WEHI-3B JCS cells. This indicated that 
fluvastatin induced apoptosis in a caspase-dependent manner. Both the intrinsic 
and extrinsic pathways were involved due to the activation of caspase-9 and 
caspase-8 respectively. In addition, the broad-spectrum caspase inhibitor only 
suppressed the caspase activities to a small extent. This result implied the 
existence of caspase-independent pathways in fluvastatin-induced apoptosis. 
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AIF is one of the pro-apoptotic proteins present in the mitochondrial 
intermembrane space and is released in response to death stimuli (Joza et aL, 
2001). It was found that fluvastatin up-regulated the protein expression of 
cytosolic AIF with a down-regulation of mitochondrial AIF protein expression in 
WEHI-3B JCS cells, suggesting the translocation of AIF from the mitochondria 
to the cytosol. Once in the cytosol, the protein would translocate to the nucleus, 
resulting in chromatin condensation and DNA fragmentation, in a 
caspase-independent manner (Amoult et al., 2002; Hong et al., 2004; Otera et al., 
2005). 
To sum up, our results showed that fluvastatin could induce apoptosis in the 
murine myelomonocytic leukemia WEHI-3B JCS cells, which was characterized 
by chromatin condensation and DNA fragmentation in the treated cells. These 
events were associated with mitochondrial membrane depolarization, activation 
of caspase-3, -8 and -9, as well as the release of AIF from the mitochondria to the 
cytosol. It has been reported that apoptosis can be triggered by the 
caspase-dependent and independent pathways. For instance, activated caspase-3 
would activate CAD in the caspase-dependent pathway (Kajstura et al., 2007), 
while AIF would translocate to the nucleus in the caspase-independent pathway 
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(Ly et al., 2003), leading to DNA fragmentation in both cases. As a result, 
caspases and AIF would independently mediate the execution phase of apoptosis 
(Perez-Galan et al., 2002). This proposed fluvastatin-induced apoptotic pathway 
was summarized in Figure 4.14. 
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Figure 4.14 The proposed fluvastatin-induced apoptotic pathway in the 
murine myelomonocytic leukemia WEHI-3B JCS cells. 
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To investigate the differentiation-inducing effect of fluvastatin, the morphology, 
cell size and granularity of WEHI-3B JCS cells were examined. It was observed 
that there was a decrease in nucleus to cytoplasm ratio, the presence of 
cytoplasmic vacuoles and an increase in cell granularity, which are 
characteristics of the monocytic differentiation of leukemia cells (Lui et al., 2005; 
Hu et al, 2010). Our results are in agreement with others showing that statins 
can stimulate the differentiation of APL cells (Sanchez-Martin et al., 2007; 
Sassano et al., 2007). Whether fluvastatin can induce the functional 
differentiation of WEHI-3B JCS cells is an intriguing aspect that is worthy of 
future investigation. 
Previous reports have suggested the immunomodulatory effects of statins 
(Montero et al., 2000; Forrester et al., 2007). In this study, fluvastatin increased 
the levels of NO generated by LPS-treated murine peritoneal macrophages. 
Interestingly, no effect on NO production was observed in the absence of LPS 
(data not shown). Accordingly, fluvastatin enhanced the effect of LPS on 
macrophage activation, but it was incapable of activating macrophages when 
used alone. Similarly, simvastatin was shown to augment the LPS-induced 
IL-12p40 and TNF-a production in macrophages which then stimulate the 
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proinflammatory responses (Matsumoto et al., 2004). The observed elevation in 
NO production by fluvastatin might be due to increased mRNA and protein 
expression of the inducible NO synthase (iNOS) which had been reported in 
breast cancer cells (Kotamraju et al., 2007). This report also demonstrated that 
iNOS-mediated NO played a crucial part in the anti-proliferative and 
pro-apoptotic effects of fluvastatin and simvastatin on breast cancer cells. In 
addition, it was suggested that the effect of activating NO-producing 
macrophages resembled the activation of endogenous NO activity in tumor cells, 
which would induce metabolic hypoxia in the tumor microenvironment and 
improving radiosensitivity of the tumor cells (Jiang et al., 2010). Therefore, 
further exploration on the immunomodulatory effect of fluvastatin is of great 
importance in cancer treatment. 
To conclude, fluvastatin triggered chromatin condensation, DNA fragmentation 
and resulting in apoptosis of the WEHI-3B JCS cells. Mitochondrial membrane 
depolarization, activation of caspase-3, -8 and -9, as well as the release of AIF 
from the mitochondria to the cytosol were found to be associated with 
fluvastatin-induced apoptosis, suggesting the possible involvement of both 
caspase-dependent and caspase-independent pathways. Fluvastatin also induced 
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the differentiation of WEHI-3B JCS cells. In addition, fluvastatin enhanced NO 
production from LPS-treated murine peritoneal macrophages. All these results 
indicated that fluvastatin exhibited pleiotropic effects on the murine myeloid 
cells. 




Chapter 5 Conclusions and Future Perspectives 
Statins are pharmacological inhibitors of 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis. 
They are widely used as a hypolipidemic drug for treating hypercholesterolemia 
and cardiovascular diseases (Campbell et aL, 2006). The intermediates and 
products of the cholesterol biosynthetic pathway play a significant role in a 
variety of cellular functions, including membrane integrity, cell signaling, protein 
synthesis and cell cycle progression (Yasuda et al, 2005). Statins have been 
shown to exhibit pleiotropic effects, including anti-inflammation, 
immunomodulation, anti-angiogenesis as well as anti-tumor properties on a 
variety of cancers (Demierre et al” 2005). The cholesterol metabolism in 
leukemia ceils is dysregulated, often with the overexpression of LDL-receptor 
and HMG-CoA reductase (Li et al., 2003; Komblau et aL, 2007). This 
uncontrolled cholesterol metabolism may be responsible for resistance to 
apoptosis and chemotherapeutic agents (Peeters et al, 2006). 
In this study, fluvastatin, simvastatin, lovastatin, but not pravastatin, were shown 
to inhibit the growth of the murine myelomonocytic leukemia WEHI-3B JCS 
cells, the human promyelocytic leukemia HL-60 cells and the murine 
macrophage-like tumor PU5-1.8 cells. The difference in the anti-leukemic effects 
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of the various statins may be resulted from their hydrophobicity, as lipophilic 
statins (fluvastatin, simvastatin and lovastatin) can directly cross the membrane 
lipid bilayer while cell entry of hydrophilic statins (pravastatin) depends on 
carrier-mediated uptake (Bellosta et al, 2004). 
The anti-proliferative effect of fluvastatin on WEHI-3B JCS cells was shown to 
be both dose- and time-dependent, but partially reversible during the early period 
(within 24 hours) of drug exposure. Fluvastatin exhibited minimal cytotoxicity to 
WEHI-3B JCS cells and no cytotoxicity in thioglycollate-elicited murine 
peritoneal macrophages, implying that it is relatively non-toxic to the normal 
myeloid cells. In addition, fluvastatin significantly diminished the in vivo 
tumorigenicity of WEHI-3B JCS cells in syngeneic BALB/c mice，demonstrating 
that fluvastatin was able to exhibit anti-leukemic effect both in vitro and in vivo. 
The underlying mechanism for the observed anti-proliferative effect of 
fluvastatin on WEHI-3B JCS cells was then investigated. It was found that 
fluvastatin suppressed the production of isoprenoid intermediates in the 
cholesterol biosynthesis pathway, which in turn inhibited the isoprenylation of 
proteins that are important for cell proliferation and survival. Fluvastatin halted 
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the cell cycle at GQ/GI phase by the down-regulation of cyclin E, cdk2 and cdk6 
protein expression. It also triggered apoptosis in both caspase-dependent and 
caspase-independent maimer by inducing mitochondrial membrane 
depolarization, activation of caspase-3, -8 and -9, AIF release from the 
mitochondria to the cytosol, chromatin condensation and nuclear fragmentation. 
Furthermore, fluvastatin also induced the morphological differentiation of 
WEHI-3B JCS cells and enhanced NO production from LPS-treated murine 
peritoneal macrophages. 
In order to provide better insights for the modulatory effects of fluvastatin on 
myeloid leukemia cells, a number of experiments have to be performed in the 
future. In the cell cycle progression, cdk inhibitors (ckis) are known to suppress 
the activities of cdks (Vermeulen et al., 2003). Thus, the protein expression of 
ckis which can inactivate cdks or cyclin/cdk complexes responsible for Gi phase, 
such as p21 and p27, should be studied so as to have a better understanding on 
the fluvastatin-mediated cell cycle arrest at GQ/GI phase. For the 
fluvastatin-induced apoptosis, the role of Bcl-2 family proteins and death 
receptors can be evaluated by investigating the protein expression of pro- and 
anti-apoptotic proteins such as Bax，Bid or Bcl-2 as well as the death receptors 
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such as TNF or Fas so as to examine the molecular mechanisms involved in 
fluvastatin-triggered intrinsic and extrinsic apoptotic pathways. Phenotypic 
studies on the cell surface expression of lineage-specific differentiation markers 
(e.g. F4/80 and Mac-1) and functional studies on the induction of phagocytic and 
endocytic activities of fluvastatin-treated WEHI-3B JCS cells should be 
performed so as to further confirm the differentiation-inducing effect of 
fluvastatin. 
In conclusion, fluvastatin showed in vitro and in vivo anti-proliferative effect on 
the murine myelomonocytic leukemia WEHI-3B JCS cells by inducing cell cycle 
arrest, apoptosis and differentiation. It also exhibited immunomodulatory effect 
on the murine peritoneal macrophages. Whether fluvastatin can act in synergy 
with hematopoietic cytokines in the treatment of myeloid leukemia is an 
intriguing aspect that awaits future investigations. Moreover, further studies, 
such as oral or parenteral administration of fluvastatin in leukemia-bearing mice, 
are needed to explore the therapeutic potential and e伍cacy of fluvastatin for the 
treatment of leukemia. 
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